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Abstract 
Hepatocellular carcinoma (HCQ is one of the commonest cancers worldwide. There is, however, a 
marked geographical variation in incidence and it has been suggested that the pathogenesis may 
vary in different parts of the world. 
A retrospective analysis of 110 HCC patients was initially undertaken which confirmed that only 
29% of British patients had markers of hepatitis B infection, suggesting a possible role for other 
environmental agents in the pathogenesis, and that 80% of patients had underlying cirrhosis. 
The nature of the strong relationship between HCC and cirrhosis has not been established but it has 
been postulated that increased hepatocyte turnover in the cirrhotic liver may predispose to DNA 
damage by environmental mutagens. Cell proliferation is required to express the strongly 
promutagenic DNA base lesion 0'-methylguanine, produced by alkylating agents, as a mutation. &- 
methylguanine is repaired by the DNA repair enzyme 06-methylguanine-DNA methyltTansferase 
(06-MT). A microassay was developed which could reliably measure 06-MT levels in liver biopsy 
samples. Using this approach 06-MT levels were found to be significantly lower in cirrhotic liver 
when compared to non-cirrhotic and normal liver tissue. No correlation was found between 
lymphocyte and liver levels from individual patients with liver disease indicating that the deficiency 
in DNA repair is disease- and tissue-specific. 
Three polyclonal antibodies were subsequently raised to 06-MT peptides and characterised by 
immunoblotting in an attempt to establish the tissue distribution of the enzyme in liver. Although 
none of the antisera were able to detect &-MT in tissue sections they were used to analyse structural 
differences in the enzyme between cirrhotic and non-cirrhotic liver using SDS-PAGE followed by 
immunoblotting and fluorography. A band of M, 24,000, representing native enzyme, was visualised 
by fluorography in all liver extracts. Densitometry of these bands correlated with the enzyme activity 
determined by the direct enzyme assay, validating the assay findings. Other small molecular weight 
bands were seen in all liver extracts and comparison with immunoblots suggested that these bands 
represent C-terminal truncated enzyme. The spectrum of smaller molecular weight enzyme forms 
was similar in cirrhotic and non-cirrhotic liver. It was, thus, concluded that although 06-MT levels 
were lower in'cirrhosis this was not accounted for by structural differences in the enzyme. 
DNA mutations (G to A) produced by the failure to repair 06-methylguanine are known to activate 
oncogenes and turnour suppressor genes such as p53. However only 5/55 (9%) of HCC expressed 
mutant p53. Other factors potentially involved in hepatocarcinogenesis include the growth factor 
TGF-a and a growth factor receptor encoded by the c-erb B-2 proto-oncogene. Expression of TGF-a 
and the C-erb B-2 oncoprotein were seen in 8/28 (28%) and 2/26 (8%) of HCC respectively, findings 
which differ from those observed in HCC from the Far East. 
Deficient DNA repair by &-MT provides one possible reason why cirrhosis is an important risk 
factor for the development of HCC. However, failure to repair 06-mothylguanine does not result in 
mutations within the p53 gene in British HCC. Furthermore, the finding of low expression of mutant 
p53, TGF-a and the c-erb B-2 oncoprotein in HCC from Britain compared to HCC from the Far East 
and Africa suggests geographical differences in the molecular mechanisms involved in 
hepatocarcinogenesis between areas of high and low HCC prevalence. 
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Chapter 1 
Introduction 
1.1 Hepatocellular carcinoma 
1.1.1 Background 
Primary liver tumours can be classified histologically as either epithelial or mesenchymal. Epithelial 
turnours include hepatocellular carcinomas (HCC), intrahepatic cholangiocarcinomas and 
hepatoblastomas whereas mesenchymal turnours, accounting for only 1% of primary liver 
malignancies, include angiosarcornas, epithelial haernangioendotheliomas and undifferentiated 
sarcomas. 
Hepatocellular carcinoma (HCQ is a malignant tumour of hepatocytes and accounts for 80% of 
primary liver turnours. Histologically HCC usually has either a trabecular or a pseudoglandular 
(adenoid) architecture but other rarer histological subtypes are also recognised such as fibrolamellar 
turnours which occur at a younger age and carry a better prognosis. A clear cell variant of HCC is 
also described and there is some evidence that this also carries a more favourable prognosis. 
1.1.2 Incidence 
Hepatocellular carcinoma remains one of the commonest cancers worldwide with 251,000 new cases 
reported each year (Parkin et at, 1988). It accounts for 4% of all turnours and is the seventh 
commonest cancer worldwide. Recent studies have also suggested that the incidence is increasing in 
Northern Europe, where there has been a3 fold increase over the last 20 years, and in Japan (Bosch 
and Munoz, 1991). An important feature of HCC is the remarkable geographical variation in 
incidence. Age-standardised yearly incidence rates vary from <4 per 100,000 in the UK to 50 per 
100,000 in China and Hong Kong, and >100 per 100,000 in Mozambique (Cook-Mozaffari et at, 1984). 
Thus 45% of new cases occur in China, 10% in Africa and 6% in Europe. 
1.1.3 Aetiology 
The striking worldwide variation in incidence suggests an important role for environmental factors 
in the aetiology of HCC (reviewed by Bassendine, 1987). Factors implicated include viruses and 
chemicals; there, is evidence of geographical variation in exposure to these agents amongst HCC 
patients. Epidemiological evidence also indicates that the aetiology of HCC is probably multifactorial 
with individual exposure OCCUTing to more than one potential carcinogen (Bassendine, 1987). 
1.1.3.1 Age and sex 
The incidence of HCC increases with age; this feature is in common with other human malignancies 
(Goodwin et al, 1986). However, there are also some geographical differences in that the peak age of 
onset is earlier, at 37 years, in South Africa ( Kew and Geddes, 1982) compared to 65 years in Japan 
and Northern Europe (The Liver Cancer Study Group Of Japan, 1987; Dunk et al, 1988). 
HCC occurs more frequently in men with a male. to female ratio of up to 8: 1 in South East Asia (Lai et 
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al, 1981) and a ratio of 3: 1 in Northern Europe (Ihde et al, 1974). In the West this male predominance 
is accounted for by the presence of HCC complicating cirrhosis, non-cirrhotic HCC having a 1: 1 male 
to female ratio (Melia et al, 1984) whereas in Japan the male predominance exists for both cirrhotics, 
and non-cirrhotics (Okuda et al, 1980). Although the relationship between male sex and HCC is not 
fully resolved the finding of a raised oestrone to testosterone ratio in male cirrhotic patients with 
HCC compared to those with cirrhosis alone has led to the hypothesis that hyperoestrogenaernia is a 
risk factor for HCC (Nagasue et al, 1985). Oestrogens increase the number of liver turnours in animal 
models of hepatocarcinogenesis (Wanless and Medline, 1982) and higher levels of oestrogen 
receptors have been reported in tumour when compared to surrounding normal liver (Sainsbury et 
al, 1984). Long term use of the oestrogen-containing contraceptive pill, is associated with the 
development of HCC (Goodman and Ishak, 1982, Neuberger et al, 1986); although this relationship 
is controversal. 
1.1.3.2 Viruses 
Hepatitis B 
There is strong epidemiological evidence supporting an aetiological role for chronic hepatitis B 
infection in HCC, with a worldwide correlation between the incidence of HCC and prevalence of the 
HBsAg carrier-state (Szmuness, 1978). This relationship has been confirmed by case-controlled 
studies showing a twenty-fold increased relative risk of developing HCC in association with chronic 
HBV infection (Yeh et al, 1985). Prospective studies of HBsAg carriers from high and low incidence 
areas also show a high relative risk (50-100 fold) of developing HCC (Beasley et al, 1981; Hall et al, 
1985). HBV-related cirrhosis also carries a higher risk of malignancy than other types of cirrhosis 
(reviewed by Slagle et al, 1992). However, the mechanisms involved in hepatitis B-related 
hepatocarcinogenesis are still unresolved. Integrated HBV DNA sequences have been detected in 
chromosomal DNA in tumour liver but these occur randomly (Himo et al, 1984; Shafritz and Kew, 
1981) and it is therefore unclear how these viral sequences can uniformally disrupt normal 
hepatocyte function leading to tumour production. 
Hepatitis C 
Hepatitis C (HCV) is an RNA virus which is now recognised as a major cause of non-A non-B 
hepatitis (Choo, 1990) and a risk factor for HCC. The prevalence of HCV infection in the normal 
population varies geographically, from 0.18% in Great Britain (Brind et al, 1990) to 0.5% in Italy 
(Sirchia et al, 1989) and 3% in Japan (Tanaka et al, 1991). Antibodies to HCV have been detected in up 
to 80% of patients with HCC. However, there is a marked geographical variation with serological 
evidence of HCV infection in HCC patients varying from 12% in China (Lee et al, 1992) and 29% in 
South Africa (Kew, 1990) to 51% in Japan (Tanaka ef al, 1991) and 65% in Italy (Colombo et al, 1989). 
There is as yet no data on the prevalence of hepatitis C infection in HCC in Britain. A recent study 
has looked for evidence of active viral replication in HCC and identified HCV RNA In the serum of 
35 % of Swiss patients with HCC (Garson et al, 1992). HCV RNA has also been detected in malignant 
hepatocytes (Chou et al, 1991). These findings together with the studies using HCV serology are very 
suggestive of a role for HCV in the pathogenesis of HCC. 
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1.1.3.3 Chemicals 
A wide variety of chemicals, including N-nitroso compounds and chlorinated hydrocarbons, are 
known to produce liver cell turnours in experimental animals (reviewed by Grasso, 1987). Although 
man is exposed to many of these compounds, which are ubiquitous environmental chemicals, a link 
between such agents and HCC has not been fully explored. The potential role for N-nitroso 
compounds in human hepatocarcinogenesis is discussed later in this chapter. It is, however, known 
that exposure to other chemicals such as organic solvents results in a2 fold increased risk of 
developing HCC Wardell et al, 1984 ). The link between HCC in China and exposure to drinking 
water obtained from stagnant ponds has led to speculation that exposure to organochloride 
pesticides may also be involved in hepatocarcinogenesis (Delong, 1979). 
Aflatoxin B, is produced by certain strains of Aspergillus flavus, which contaminates cereals and 
nuts during storage. It is a recognised carcinogen in animal models, inducing hepatocellular 
carcinoma in rats and primates (Busby and Wogan, 1984). In man, epidemiological evidence has 
linked exposure to aflatoxin with HCC in Africa (Linsell and Peers, 1977) , Far East (Yaobin et al, 
1983), and South Africa (Kew et al, 1993). It is accepted that exposure to aflatoxin is low in Japan and 
Europe but this is based on the lack of exposure to stored foods known to be contaminated by 
aspergillus and has not been established epidemiologically. Aflatoxin has been found in the serum 
and liver of patients with HCC (Onyemelukwe et al, 1982) and DNA adducts, which aflatoxin forms 
with guanine in DNA (Muench et al 1983), have also been identified in liver tumour tissue (Zhang et 
al, 1991). However, a direct causal role for aflatoxin in man is unproven and any association between 
aflatoxin and other risk factors such as hepatitis B infection, which is high in areas of high aflatoxin 
exposure, remains to be characterised. 
1.1.4 Clinical features 
HCC is a turnour with a poor prognosis (reviewed by Johnson, 1987); the overall median survival is 4 
months. Early diagnosis is difficult as symptoms are usually non-specific and most turnours present 
at a late stage. The recognition that the majority of patients with HCC have underlying cirrhosis has 
led to screening of cirrhotic patients by serum alpha fetoprotein estimations and hepatic ultrasound 
scanning (Okuda, 1986). This has resulted in the detection of early turnours in Japan which are 
amenable to surgery with some improvement in prognosis. These results, however, have not been 
reproduced in Europe (Colombo et al, 1991). The only curative treatment for HCC is surgical 
resection or liver transplantation but few patients are suitable candidates because of advanced 
turnour stage at diagnosis (reviewed Guest and Blumgart, 1987; Poulson et al, 1987). There have been 
few advances in chemotherapy for HCC which essentially remains palliative (reviewed Dunk and 
Thomas, 1988). 
Improvement in the prognosis of HCC, which thus remains a common, rapidly growing, 
chemotherapeutic resistant turnour, is likely to depend on an improvement in our understanding of 
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the mechanisms involved in hepatocarcinogenesis, such as those involved in the malignant 
transformation of cirrhotic liver and the factors contributing to the rapid growth of the tumour. 
1.2 Cirrhosis as a preneoplastic lesion 
A close association exists between cirrhosis and HCC. This is based on the finding of a high 
prevalence of cirrhosis in patients with HCC and on the observation of an increased risk of patients 
with cirrhosis developing HCC. In 60-90% of all cases of HCC, cirrhosis is present in the adjacent 
liver and unlike other postulated aetiological factors, there is less geographical variation in the 
prevalence of cirrhosis in HCC patients (Table 1.2). Cirrhosis is thus an important worldwide risk 
factor for the development of HCC. 
Table 1.2: Worldwide incidence of cirrhosis in patients with HCC. 
Country Incidence of HCC % of IICC patients Reference 
with cirrhosis 
South Africa High 61 ' Kew et al, 1992 
Japan Intermediate 80 Nagasue et al, 1984 
Italy Intermediate 95 Villa et at, 1988 
Britain Low 80 Dunk et al, 1988 
Cirrhosis is a pathological diagnosis made on the basis of loss of the normal liver architecture with 
the formation of regenerating nodules and fibrosis. It occurs as the result of chronic liver cell damage 
such as occurs through hepatitis B infection and immune mediated damage in chronic autoimmune 
liver disease. Cirrhosis can be subdivided, according to its aetiology, as follows: (i) viral; hepatitis B 
and C, (ii) toxins; alcohol, (iii) autoimmune; primary biliary cirrhosis and chronic active hepatitis, 
and (iv) metabolic; haernochromatosis, Wilsons disease and alpha 1 antitrypsin deficiency. In some 
cases the aetiology is not apparant (cryptogenic cirrhosis). The aetiology of cirrhosis also varies 
geographically; hepatitis B being the commonest cause in the Far East and alcohol the major 
aetiological factor in Northern Europe. 
The risk of cirrhotic patients developing HCC depends on it's aetiology, hepatitis 13-related cirrhosis 
and haernochromatosis carry a much greater risk than primary biliary cirrhosis (Bassendine, 1987). 
Despite the strong association between cirrhosis and HCC the nature of the relationship between 
cirrhosis and HCC has not been established. One hypothesis is that the raised rate of DNA synthesis 
that accompanies the formation of hyperplastic nodules in cirrhosis could act as a promoter for cells 
already initiated by exposure to a primary carcinogen, viral or chemical. The development of 
methodology to measure DNA synthesis, in vitro, in liver biopsies using uptake of 
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bromodeoxyuridine (BrDU), a thymidine analogue, taken up by S phase cells and detected using 
anti-BrdU antibodies, has allowed indirect assessment of cell proliferation in cirrhotic tissue 
(Gratzner, 1982). Using this technique, DNA synthesis was found to be higher in cirrhotic tissue 
adjacent to tumour involved tissue than in cirrhotic tissue taken from patients without HCC (Tarao et 
al, 1989) and a prospective study of cirrhotic patients has shown an increased risk of developing 
HCC in those patients with higher levels of DNA synthesis (Tarao et al, 1992). Cells within cirrhotic 
tissue are therefore arguably at increased risk of damage from environmental carcinogens, both viral 
and chemical. 
1.3 Chemical carcinogenesis 
Turnorigenesis in humans in a complex multistep process (reviewed by Weinberg, 1989; Fearson and 
Vogelstein, 1990; Bishop, 1987). It can only be studied indirectly in man and most of our 
understanding of the molecular mechanisms involved comes from studies in animals. Experimental 
carcinogenesis has traditionally been divided into three steps; initiation, promotion and progression 
(Archer, 1987). Although this is an oversimplification of a complex pattern of events, it does serve as 
a useful frame work when examining elements involved in chemical carcinogenesis. Initiation is an 
irreversible process by which chemical carcinogens or ionizing radiation causes permanent DNA 
damage in target cells. Chemical damage can be mediated through exposure to environmental 
carcinogens or to endogenous carcinogens (Ames, 1990). Epidemiological evidence has linked 
occupational exposure to various chemicals with the development of human tumours (reviewed 
Archer, 1987). Thus, exposure to polycyclic hydrocarbons is linked to scrotal cancer and 
napthylamine exposure with bladder cancer. The liver is also susceptible to damage by chemical 
carcinogens as exemplified by the strong link between vinyl chloride exposure and the development 
of hepatic angiosarcoma (Berk, 1976). The ultimate effect of chemically-induced DNA damage is 
dependent on the presence of DNA repair mechanisms. If damage is not repaired prior to DNA 
replication then it will become fixed in the daughter cells . An important type of damage appears to 
be activation of oncogenes and/or alteration of the function of turnour suppressor genes by point 
mutations. Oncogenes, such as the activated ras genes, are mutated forms of normal cellular genes, 
proto-oncogenes, which are normally involved in regulating cell proliferation and differentiation 
(Bishop, 1987). Thus, oncogene activation through mutation leads to loss of normal control of cell 
growth. The pattern of oncogene activation appears to depend on turnour type and chemical 
carcinogen, with exposure to certain carcinogens being associated with specific mutations. 
Promotion has been defined as the process whereby turnour formation is stimulated in tissues that 
have been exposed to an initiating agent (Archer, 1987). Cellular proliferation, or mitogenesis, is also 
an important factor in the process of carcinogenesis (Weinberg 1989) as exemplified by the use of 
tumour promoting agents (often chemicals), which increase cell turnover, in animal models of 
chemical carcinogenesis. Other factors that affect cell proliferation include oncogenes and growth 
factors. As well as causing mutations exposure to chemical carcinogens can also lead to cell death. 
This results in secondary cell proliferation and in this way chemical carcinogens can also act as 
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promotors (Ames 1990). Figure 1.3 illustrates the interplay between the exposure to chemical 
carcinogens, cell proliferation and tumour production. 
1.4 Chemical hepatocarcinogenesis 
1.4.1 Susceptibility of human liver to chemical carcinogens 
Exposure to environmental factors, such as aflatoxin and hepatitis B, are known from 
epidemiological studies to be associated with the pathogenesis of human HCC. In Britain, however, 
exposure to aflatoxin is low and a significant number of patients with HCC have no markers of 
hepatitis B infection, suggesting that other environmental carcinogens may be important in the 
development of HCC. 
The susceptibility of human liver to carcinogenic damage by environmental compounds depends on 
the following four factors (Craddock, 1986) 
(1) The ability of the liver to metabolise the compounds to metabolites capable of reacting with 
DNA. 
(2) The extent and specificity of DNA base damage produced., 
(3) The presence of a repair mechanism capable of reversing DNA base damage prior to replication. 
(4) The extent of DNA Teplication which will'fix'any DNA damage as a mutation in newly divided 
cells. 
The N-nitroso compounds are candidate carcinogens as they are ubiquitous environmental 
compounds which are primarily metabolised in the liver and cause DNA base damage which, if not 
repaired, results in G to A mutations which are known to activate oncogenes and tumour suppressor 
genes. These compounds are also recognised carcinogens in rodent models of hepatocarcinogenesis 
(Grasso et al , 1977). 
1.4.2 N-nitroso compounds 
Human exposure to N-nitroso compounds occurs in occupational and other environmental settings 
(reviewed by Bartsch and Montesano 1984). Occupational exposure occurs, for example, in the dry 
cleaning and petrol station service industries, and epidemiological evidence has shown that such 
workers are at risk of developing HCC (Sternhagen et al, 1983). Evidence for the carcinogenicity of 
N-nitroso compounds in food was recently strengthened by a case-controlled study from China that 
linked ingestion of N-nitroso compounds with oesophageal cancer (Cheng et al, 1992). Endogenous 
exposure to nitrosamines, produced in vivo from precursor amines, is thought by some (Bartsch and 
Montesano, 1984) to be more important than exogenous exposure from environmental sources. 
However, methods for quantifying the extent of nitrosamine exposure, both exogenous and 
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endogenous, in humans are still being developed and so most of the evidence on the carcinogenic 
effect of nitrosamines on the liver relies on animal models (Fine, 1982). 
N-nitroso compounds fall into two classes, the N-nitosamines and the N-nitrosamides. N- 
nitrosarnides (e. g. methylnitrosurea) are characteristically unstable at physiological pH and rapidly 
decompose to reactive intermediates. In contrast, nitrosamines (e. g. dimethylnitrosurea) are 
relatively stable with their action on DNA being through active metabolites that are produced in cells 
by enzyme action (Montesano, 1981). Unlike many other chemical carcinogens, whose turnorgenicity 
in animals is species-specific, N-nitroso compounds produce liver turnours across the complete 
spectrum of animal species (Bogoviski et al, 1981). Carcinogens that are commonly used in rodent 
models of chemical hepatocarcinogenesis include the nitrosamines, dimethylnitrosourea and 
diethylnitrosourea, and the nitrosamide, methylnitrosourea (Farber and Cameron, 1980). N-nitroso 
compounds are alkylating agents which are capable of forming alkyl adducts at 12 different DNA 
base sites. The relative proportion of alkylation at the nitrogen and oxygen atoms of the purine and 
pyramidine bases, such as the &position of guanine and the 04position of thymine, depends upon 
the alkylating agent (reviewed by Montesano, 1981). 
1.4.3 06- alkylguanine 
Not all alkylating agents are carcinogens in animal models, but those compounds that are most 
carcinogenic produce alkyl adducts at the 06 position of guanine (Loveless, 1969). Work in rodents 
has also linked exposure to alkylating agents with the presence of &-alkylguanine, mutagenicity 
and carcinogenicity (Goth and Rajewsky, 1974; Newbold et al, 1980; Bartech et al, 1983). Thus, 
although 06-alkylguanine is not the most frequent DNA lesion induced by alkylating agents, it is 
biologically more important in terms of its association with malignant change. 
&-alkylguanine, unlike native guanine in DNA, is unable to pair with cytosine on DNA replication 
but mispairs with thymine. This results, in a GC to 'AT transition mutation (Coulondre and Miller, 
1977; Eadie et al, 1984), shown schematically in Figure 1A3. The mechanism underlying this non- 
complementary base pairing is still a subject of debate (Loveless, 1969; Swann, 1990). 
Evidence that these G to A mutations are carcinogenic through activation of oncogenes comes from 
the several different lines of experimental evidence. Firstly, the finding that single low dose 
nitrosamines consistently induce mammary tumours in rats which contain G to A mutations in the 
H-ras oncogene (Zarbl et al, 1985), and that nitrosamines produce similar mutations in skin turnours 
(Brown et al, 1990). Secondly, the finding of G to A mutations in the tumour suppressor gene p53 in 
rat oesophageal and kidney turnours induced by N-nitroso compounds (Ohgaki et al, 1992). The 
mutations within the H-ras proto-oncogene are consistently in the second base of codon 12 with the 
sequence 5'-CTGGA-3'. In the rat, oesophageal turnours mutations were also restricted to specific 
bases within two codons in exon 6 of the p53 gene (i. e. the second guanine in CGG [codon 2131 and 
the first guanine in GAG [codon 2041 ). The specificity of these mutations seems in part to be due to 
the ability of the nitrosamines (Mitra, 1989; Georgiadis, 1991) to gain access to certain guanine 
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residues and partly the effect of neighbouring bases on miscoding by DNA polymerase (Singer et al, 
1989). There is also indirect evidence in Exo1i for sequence-specificity of DNA repair which may also 
contribute to the apparent non-random nature of these mutations (Topal et al, 1986; Topal, 1988). 
1.4.4 Importance of cell proliferation 
Cell proliferation is pivotal to the process of chemical carcinogenesis. DNA replication is needed to 
convert the promutagenic DNA base lesion 06-alkylguanine into a mutation. Furthermore, the 
increased cell turnover increases the number of mutated cells, thus allowing them to overcome 
growth inhibitory properties of surrounding cells and also increases the chance of further mutations. 
The importance of cell turnover is reflected in the use of agents or 'promotors' known to cause cell 
proliferation in most of the models of rodent chemical hepatocarcinogenesis (reviewed by Farber and 
Cameron, 1980). Agents used include phenobarbitone and carbon tetrachloride which increase the 
yield of liver turnours produced following a single dose of the chemical carcinogen 
dimethy1nitrosamine (Weisburger et al, 1975). The action of phenobarbitone is probably mediated via 
direct increased cell turnover and enhanced xenobiotic metabolism whereas carbon tetrachloride 
causes hepatocyte necrosis which leads to secondary cell proliferation associated with tissue repair. It 
has been postulated that the cell necrosis with secondary proliferation, or mitogenesis, that is seen 4 
following exposure to a carcinogen may in itself be enough both to initiate and promote the 
appearance of turnours (Ames, 1990). This may explain why, in rodents, the number of HCC 
forming can be increased by the use of increasing doses of nitrosamines alone, nitrosamines are 
known to produce hepatocyte necrosis in a dose dependant manner (Solt and Farber, 1976). 
Another important agent for increasing cell proliferation commonly used in rodent models of 
hepatocarcinogenesis is partial hepatectomy. The response of the liver to partial hepatectomy is 
restorative increased cellular proliferation with DNA synthesis peaking 24 hours later (Mead and 
Fausto, 1989). Partial hepatectomy, coupled with an exposure to nitrosamines results in the formation 
of preneoplastic or dysplastic foci in rats, whereas no such foci are observed when the rats receive the 
same carcinogen with a sham operation (Columbano et al, 1981). In another study, more tumours 
were observed when nitrosamines were administered at increasing times after the hepatectomy, with 
most tumours occuring when the carcinogen was given 24-48 hours later, a time when cell 
proliferation was maximal (Pound and Lawson, 1975). 
Figure 1.4.4 shows the mechanism whereby HCC may develop in cirrhotic tissue following exposure 
to environmental alkylating agents thus potentially explaining why cirrhosis is a risk factor for HCC. 
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1.5 DNA repair 
DNA repair mechanisms are important in protecting cells from both spontaneous and 
environmentally induced DNA damage (reviewed by Friedberg, 1985). DNA damage can be caused 
by chemicals and physical agents such as ultraviolet and ionizing irradiation. Chemicals can damage 
DNA by the process of alkylation (as discussed above), or the formation of DNA-DNA or DNA- 
protein crosslinks. There are many repair mechanisms now known to deal with such damage 
including; (a) those that reverse DNA damage, such as the repair of single strand breaks, (b) excision 
repair, either nucleotide or base excision, and W post-replication repair. Defects in DNA repair 
mechanisms are linked to the development of some inherited cancers. This is exemplified by 
xeroderma pigmentosa, where a defect in excision repair of DNA containing thymidine dimers 
caused by UV light, results in skin cancer. The contribution made by defects in DNA repair to the 
development of sporadic tumours has still to be determined. 
The promutagenic DNA base lesion &-alkylguanine, produced by alkylating agents, is repaired by 
the unusual DNA repair enzyme 06- methylguanine-DNA methyltransferase (06 MT, also 
abbreviated to MGMT) which acts by removing alkyl groups from the 06 position of guanine 
restoring native guanine in DNA prior to DNA replication( reviewed by Pegg 1990; Strauss, 1990). 
1.6 06. methylguanine-DNA methyltransf erase 
1.6.1 Background 
d-MT was first identified in Escherichia coli as aA 39,000 protein, encoded by the ada gene. it 
consists of two domains separated by a hinge region sensitive to endogenous protease action 
(Bhattacharyya et al, 1988a). The protein is split by proteolytic cleavage and the resulting Mr 19,000 
carboxy terminal fragment repairs 0'-alkylguanine. E. coli also contains a second gene, ogt, that 
encodes a protein of Mr 19,000. The ogt protein displays a 29% homology with the carboxy terminal 
domain product of the ada gene and is also able to repair 06-methylguanine (Potter et al, 1987). 
Methylation of the ada protein at cysteine 69 converts the ada protein into a strong transcriptional 
activator of its own gene (reviewed by Lindahl et al, 1988). Such a mechanism is the basis of the so 
called "adaptive response" whereby levels of, the enzyme are induced in response to alkylation 
damage so increasing the repair capacity of the cell for these adducts. In contrast to the ada gene 
product the ogt gene protein is not induced in this manner (Wilkinson et al, 1989). 
Similar alkyltransferase enzymes have now also been identified, and the gene encoding the enzymes 
cloned, in other bacteria (Rebeck et al, 1989), yeast (Sassanfar and Samson, 1990), rodents (Wilkinson 
et al, 1990) and man. 
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1.6.2 Function 
&-MT acts by removing alkyl groups from the & position of guanine in DNA which it transfers to 
its own specific cysteine residue, so restoring native guanine in DNA, and as a result it becomes 
inactivated (Foote et al, 1980; Pegg et al, 1983). It is therefore not strictly an enzyme as it only acts 
once but nor is it an acceptor protein as the protein itself mediates the transfer of the alkyl group 
from the DNA. The number of 06-alkyl adducts that can be repaired is therefore limited to the 
number of 06-MT molecules available. 06- methylguanine is the preferred substrate, but longer alkyl 
groups can also be removed. The repair protein is usually either referred to as 06 -methylgUaninC_ 
DNA methyltransferase or 06- alkylguanine-DNA alkyltransferase. The rate of repair decreases with 
increasing size of the alkyl group and branched chain groups are repaired more slowly than linear 
alkyl groups (Pegg et al, 1984). Unexpectedly, Cf-benzylguanine, which has a large benzene ring- 
containing structure, is a good substrate for 06-MT and therefore rapidly inactivates the protein 
(Dolan et al, 1990). There is accumulating evidence that longer alkyl adducts are repaired by both 06- 
MT and DNA excision repair processes (Bronstein et al, 1992). The exact mechanism by which these 
longer adducts are repaired is still unknown although it has been suggested that nucleotide excision 
repair enzymes may be needed for 06-MT to gain access to DNA through the complex chromatin 
structure ( Bronstein et al, 1992). Double stranded, as opposed to single stranded, DNA is also a 
preferred substrate for 06-MT. Repair of 06-methylguanine is to some extent sequence specific. By 
using oligonucleotide substrates of different sequence containing alkylguanine, Dolan et al (1988) 
showed that repair was slowest when &-methylguanine is located on the Y-side of another guanine 
residue (Dolan et al, 1988). All sequences, however, were repaired such that differences in repair 
rates are only likely to be important when the number of adducts exceeds the number of 
molecules (Dolan et al, 1988). 
1.6.3 Regulation of levels 
The human 06-MT genei which is located on chromosome 10 (Rydberg et al, 1990), consists of 5 
exons and spans over 170kb, but encodes an mRNA of only 0.95-1.0kb (Nakatsu et al, 1993). Factors 
affecting regulation of enzyme levels have been analysed using cell lines containing enzyme that is 
either detectable (so-called "Mer+") or undetectable (so-called "Mer -"). 06-MT levels are probably 
transcriptionally regulated as Mer- cells have undetectable levels of mRNA, as determined by 
Northern blotting, but with no associated gene rearrangements (Pieper et al, 1990; Ostrowski et al, 
1991a). Little is known about the regulation of &-MT gene transcription. The gene promotor region 
has been identified but only partially characterised (Harris et al, 1991; Harris et al 1992). Gene 
methylation is, however, one important factor controlling RNA levels. Increasing gene methylation 
usually correlates with decreasing cellular RNA levels (Cedar, 1988). However, there is a direct 
correlation between 0'-MT gene methylation and gene expression which may explain how basal &- 
MT levels are re-established following exposure to alkylating agents (Pieper et al, 1991a; Fritz and 
Kaina, 1992). 
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06-MT comprises only a minor proportion of total cellular protein (approximately 0.00025%) in 
human liver (Pegg, 1990). This corresponds to about 30,000 to 100,000 molecules per cell in human 
cell lines (Yarosh et a], 1983; Foote and Mitra, 1984). The normal rate of synthesis and cell turnover of 
the enzyme in human tissues is unknown. Levels of the E coli enzyme increase up to 100-fold in 
response to alkylation (reviewed by Lindahl et al, 1988). Furthermore, levels of the rodent enzyme 
have been reported to increase, although only of the order of 3-fold, in response to stimuli such as 
partial hepatectomy (Pegg et al, 1981a) and non-alkylating hepatotoxins (Pegg and Perry, 1981b). 
Initial studies on human cell line; s suggested that 06-MT levels could be induced by exposure to 
alkylating agents, which deplete active enzyme levels, but only of the order of about 3-fold 
(Waldstein et al, 1982a). However, this has not been confirmed by other groups using the same cell 
lines (Yarosh et al, 1984; Foote and Mitra, 1984). A recent study using the colorectal cell line HT29 
showed no induction of enzyme synthesis following exposure to N-nitroso compounds, and that 
basal enzyme levels are only restored slowly at around 700 molecules/cell /hour (Pieper et al, 1991b). 
The effect of other exogenous factors such as cell proliferation and ionizing radiation on human 01- 
MT levels remains unknown although interestingly, cell cycle changes in &-MT levels have been 
reported (Kim et al, 1986) and the ability of human lymphocytes to restore basal levels of the enzyme 
following depletion by N -nitroso compounds appears to depend on their proliferative state (Gerson, 
1988). 
1.6.4 Human cell and tissue levels 
Human tissues and cells have a much higher content of Cf-MT than equivalent tissues from rodents, 
of the order of 5-10 fold (Gerson et al, 1986). Enzyme levels in man also differ between organs with 
the highest levels having been reported in liver and spleen and the lowest in brain (Table 1.6.4 ). 
Table 1.6.4: Normal human tissue 06-MT levels. 
Tissue Mean 06. MT levels Reference 
fmol/mg protein 
liver (n = 9) 
T lymphocytes (n = 10) 
Colon (n = 10) 
Stomach (n 8) 
1070 Myrnes et al, 1983 
359 Gerson et al, 1986. 
140 Myrnes et al, 1983 
600 Kyrtopoulos et al, 1984 
Brain (n = 4) 76 Wiestler et a], 1984 
The possibility that deficiency in 06-MT levels may increase cell and tissue susceptibility to 
carcinogens has led many groups to measure enzyme levels in human tumour cell lines and turnour 
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tissue. A striking early observation was the finding of undetectable levels of 06_MT in a large 
number of malignant cell lines implicating deficient DNA repair in the process of carcinogenicity 
(reviewed by Strauss, 1990). However, the discovery of an &-MT deficient tumour cell line which 
had been derived from a cell containing detectable levels of enzyme has led to the suggestion that 
loss of 06-MT may occur during culture; ie, either cell culture selects for a small population of cells 
that lack 06-MT activity or transformation leads to loss of activity. The latter is supported by the 
observation that virally transformed cells are more likely to lack &-MT than other human tumour 
cell lines (Day et al, 1980). It is also of interest that cells in culture can spontaneously either stop 
expressing 06-MT (Green et al, 1990; Day et al, 1991) or spontaneously start producing the enzyme 
(Arita et al, 1990). 
The existence of a large number of Mer- tumour cell lines has led to &-MT levels being measured in 
a range of human turnours (Citron et at, 1991; Chen et at, 1992; Myrnes et at, 1984). These studies 
have indicated that unlike tumour cell lines there are only a few turnours, such as brain 
astrocytomas, colon carcinoma and stomach carcinoma in which d-MT cannot be detected (Citron et 
at, 1991). There is also a wide interindividual variation in enzyme levels from the same turnour type 
(Citron et at, 1991; Chen et at, 1992). Studies comparing 06-MT from turnours with levels in 
surrounding tissue have provided conflicting results. Citron et at (1992) showed no difference in 
enzyme levels but Myrnes et at (1984) suggested that less enzyme was present in the turnour 
compared to the surrounding tissue. 
1.6.5 Depletion of 06_ IVIT and carcinogenesis 
There is increasing evidence that the cellular level of &-MT is an important factor in determining 
the sensitivity of cells to mutations and malignant transformation. The frequency of mutations 
following exposure to alkylating agents is higher in cells with lower levels of the DNA repair enzyme 
(Maher et al, 1990). It has also been shown that turnour cell lines which do not express 01-MT are 
more sensitive to alkylating agent induced cytotoxicity (Scudiero et al, 1984) but that introduction of 
the E coli ada gene into these cells results in increased resistance to such compounds (Ishizaki et al, 
1986). Furthermore, the presence of 06-MT appears to protects cells from spontaneous G to A 
mutations, thought to be due to endogenous 06-alkylguanine possibly produced following 
nitrosamine exposure (Aquilina et al, 1992). Finally, Dumenco et al have recently published an 
important study showing that transgenic mice expressing the human &-MT gene in their thymus 
were protected from forming thymic lymphomas containing G to A mutations in the H ras oncogene 
following exposure to nitrosamines (Dumenco et al, 1993). 
1.7 Oncogenes, tumour suppressor genes and growth factors 
Cellular oncogenes are components of signal transduction pathways their products include; 
extracellular growth factors and hormones, growth factor receptors on the cell membrane, 
cytoplasmic binding proteins and nuclear transcription factors. These pathways are pivotally 
involved in cellular proliferation and differentiation. Abnormalities of expression of these gene 
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products are important components in the multistep process of carcinogenesis (reviewed Bishop, 
1991). 
There are now over 60 recognised oncogenes (Bishop, 1991) but surprisingly few have been studied 
and implicated in human hepatocarcinogenesis. Oncogenes may be activated by mutations or gene 
amplification. Mutations include point mutations, such as the G to A mutation produced by 06_ 
alkylguanine, and deletions and rearrangements. The ras oncogenes (N-ras, K-ras and H-ras) which 
encode cytoplasmic GTP binding proteins, are an example of oncogenes that are activated by point 
mutations, and are the oncogenes most frequently implicated in the development of human turnours 
(Bos, 1989). Several studies have shown enhanced expression of ras genes in rat liver turnours 
(Makino et al, 1984; Chander et al, 1987) and elevated p2l ras protein has been detected in human 
cirrhotic nodules and HCC (Nonomura et al, 1987). However only 4 out of 20 (20%) human HCC 
have been shown to have mutations in codons 12 and 61 of the ras oncogenes and none of these were 
G to A (Challen et al, 1992a). 
Recognised tumour suppressor genes include the retinoblastoma gene (RB), p53 and DCC (deleted in 
colorectal cancer) gene. Alteration of tumour supressor gene function occurs through point 
mutations and allele loss with resulting loss of tumour suppression. The normal P53 gene product is 
believed to be involved in controlling entry of cells into S phase of the cell cycle ( Harris, 1991). p53 
mutations are common in human cancers and a significant number are G to A mutations (reviewed 
by Hollsteine et al, 1991). 
The number of recognised peptide growth factors are also increasing (reviewed Cross and Dexter, 
1991). An important group of growth factor receptors are those encoded by the c-erb BI-3 proto- 
oncogenes (reviewed Prigent and Lemoine, 1992). The protein products of these proto-oncogenes are 
a family of transmembrane proteins, which. are often overexpressed in human tumours. c-erb B-1 
encodes for the epidermal growth factor (EGF) receptor (EGFR) which is also the receptor for 
transforming growth factor alpha (TGF-a) (Todaro et al, 1980). C-erb B-2 encodes a receptor, for 
which the ligand is still unknown, whose oveTexpression correlates with prognosis in breast 
carcinoma (reviewed by Maguire and Greene, 1989). The third member of this family of growth 
factor receptors is the c-erb B-3 (Kraus et al, 1989; Plowman et al; 1990) protein product which is also 
overexpressed in human turnours, such as breast and pancreas (Lemoine et al, 1992; Lemoine et al, 
1993). Figure 1.7 illustrates the cellular location of TGF-a and the protein products of c-e rb B-2, ras, 
and p53 which can all be considered as components of the cells' signal transduction pathway 
affecting growth and differentiation. 
1.8 Alms of the study 
The overall aim of this study was to look at the molecular mechanisms involved in human 
hepatocarcinogenesis in Britain, in particular to assess possible mechanisms involved in the 
malignant transformation of cirrhotic tissue and to assess factors potentially involved in tumour 
growth. 
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In view of the known geographical differences in the aetiology and possible mechanisms of 
hepatocarcinogenesis the first aim of the study was to establish the clinical features of hepatocellular 
carcinoma in Northern England. Particular attention was paid to the prevalence of risk factors 
previously reported from other geographical areas, namely the presence of hepatitis B infection and 
cirrhosis. 
The second aim was to measure the DNA repair enzyme &-methylguanine-DNA methyltransferase 
(06-MT) in cirrhotic tissue and to compare levels with those in non-cirrhotic liver. The central 
hypothesis of this investigation was that deficient repair of 06 -methylgUanine in Cirrhotic tissue 
might increase the likelihood of G to A mutations in oncogenes; and tumour suppressor genes 
involved in the development of hepatocellular carcinoma. In order to measure 06-MT in small liver 
biopsy samples a novel enzyme microassay was developed. The relationship between enzyme levels 
in lymphocytes and liver from individual patients was also assessed to determine whether any 
deficiency in 06- MT levels was both tissue - and disease-specific. 
The third aim was to develop polyclonal antibodies to three different regions of the DNA repair 
protein &-MT to use such reagents to establish the cellular distribution of &-MT in normal and 
diseased liver by immunohistochemistry. In addition these antibodies could be used in immunoblots 
of extracts separated by SDS-PAGE to characterise different molecular weight forms of the enzyme in 
cirrhotic and non-cirrhotic liver and in lymphocytes. SDS-PAGE of radiolabelled liver and 
lymphocyte extracts followed by fluorography could therefore be used to confirm the enzyme assay 
findings. 
The fourth aim was to look at expression of the tumour suppressor gene p53 in British HCC which is 
known to be altered by mutations which include G to A transition mutations produced by the 
inability of cells to repair 06-methylguanine. The final aim was to look at growth factors that might 
also be involved in hepatocarcinogenesis, namely the expression of transforming growth factor alpha 
and the growth-factor receptor c-erb B-2 using immunohistochemistry. 
The tissue used in this study came from two sources: prospectively collected liver biopsy tissue was 
used to examine the DNA repair enzyme in cirrhotic and non-cirrhotic liver, whereas formalin-fixed 
paraffin-embedded archival liver biopsy tissue was used to study the expression of p53, c-erb B-2 
and TGF-a in hepatocellular carcinoma. 
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Chapter 2 
Clinical Features Of Hepatocellular Carcinoma 
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2.1 Introduction 
Previous studies of the clinical features of HCC have shown marked geographical differences 
(reviewed by Johnson, 1987). HCC differs between high and low incidence areas in the age of turnour 
onset, actiological factors, extent of tumour at presentation and survival (Liver Cancer Study Group 
Of Japan, 1987; Calvert et al, 1990). This suggests that the mechanisms of hepatocarcinogenesis are 
non-uniform. Although large studies of the features of HCC have been reported from areas of high 
prevalence, studies from the United Kingdom (UK) have been either small or have been carried out 
by tertiary referral centres in areas where there are large population movements. Table 2.1 shows 
that in the UK these studies have been principally undertaken in two London tertiary referral units. 
Although there is also a large study from Glasgow, this was based on post mortem data and so the 
findings can not be directly compared to antemortem data from other areas. 
Table 2.1: Studies detailing the clinical features of HCC in the United Kingdom 
Area Number Type of study Reference 
Glasgow 100 Post mortern MacSween, 1974 
London (Kings) 96 Retrospective Johnson et al, 1978 
150 Cirrhosis/non-cirrhosis Melia et al, 1984 
42 Prospective Zaman et al, 1985 
49 IMnligTants/non-immigTants Zaman et a], 1986 
London (Royal Free) 41 Retrospective Dunk et al, 1988 
The aim of this study was to establish the clinical features of HCC in a relatively stable population 
from the North East of England, thus identifying possible aetiological factors in the population in 
which the molecular mechanisms of hepatocarcinogenesis were to be studied further. 
2.2 Patients and Methods 
The study population comprised 110 consecutive patients with a histological diagnosis of primary 
hepatocellular carcinoma (HCC) seen at Freeman Hospital, Newcastle upon Tyne from 1978 to 1992. 
Full clinical details including the results of investigations, treatment and survival were obtained 
retrospectively from case notes. Clinical records were also obtained from the referring hospital in 
cases Of regional referrals. 105 patients were Caucasian of whom 99 had spent most of their life in the 
North East of England. 
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Statistical analysis 
All data collected were documented on a standard proforma, designed for transfer of information to 
the Northumbria Universities Multiple Access Computer (NUMAC). Computer instructions were 
written to read this raw data and create a systems file using SPSS-X (SPSS-X Batch System, SPSS 
Inc. Chicago, Ilinois, USA). Validation procedures were carried out to ensure accurate data 
transcription. Non-parametric statistical methods were used for comparisons between groups. 
Survival curves were calculated by the Lee-Desu statistic (Lee and Desu, 1972). The effects of age 
group, treatment and tumour stage were calculated by the Cox's regression model (Cox, 1972). 
2.3 Results 
2.3.1 Age and sex 
The median age of the 110 patients was 64 years with a range of 16 to 83 years (Figure 2.3.1). The 
male to female ratio was 7 to 3. 
2.3.2 Symptoms and signs at presentation 
The median time from the onset of symptoms to presentation was 8 weeks (range 1 to 104). 7 patients 
were asymptornatic at presentation having been identified through a-fetoprotein screening. 
Symptoms at presentation were non-specific with abdominal pain occuring in 69% but only localised 
to the right upper quadrant in 33% of these cases. Hepatornegaly was a common finding at 
presentation but evidence of chronic liver disease (CLD) such as cutaneous stigmata and /or 
splenornegaly was found in only a third of patients. (Table 2.3.2). Hepatic decompensation. in the 
form of ascites was not uncommon (34%) but encephalopathy and variceal bleeding were rare ( n--4 
and n=2 respectively) 
2.3.3 Aetiology 
Only 25% (n= 27) of patients were known to be cirrhotic at presentation although following 
subsequent investigation cirrhosis was diagnosed in 76% (75/99) of patients ( 65 cases based on 
histology of non-tumour affected liver andlO on clinical criteria where histology of tumour alone was 
available). The presence or absence of underlying cirrhosis could only be determined in 99 patients as 
in the other 11 cases only turnour was present on liver biopsy and clinical criteria were unhelpful. 
The commonest types of cirrhosis were those associated with alcohol abuse (diagnosed on the basis 
of a history of prolonged alcohol ingestion of more than 80g/day and/or histological evidence of 
alcohol-induced injury), hepatitis B infection (the presence of HBsAg or HBcAb alone in the absence 
of alcohol abuse) and 'cryptogenic' (Figure 2.3-3). A diagnosis of cryptogenic cirrhosis was made, in 
the absence of hepatitis C screening, if there was no obvious actiological factor. Hepatitis C virus 
antibody testing only became available during the last 18 months of the study. Sera from 17 patients 
were tested for hepatitis C and 4 (23%) had antibodies using the second generation RIBA test 
(Abbott). Cirrhosis in these patients had previously been diagnosed as alcoholic (n=l) and 
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Table 232: Clinical features at presentation. 
Symptoms and signs Number M of patients 
Abdominalpain 76 (699o) 
Weakness 74(67%) 
AnoreDda 64(58%) 
WdigLit loss 59(, 54%) 
Nausea 45(41%) 
Hepatomegaly 91(83%) 
jaundice 41(37%) 
Cutaneous stigmata of CIJD 38(357o) 
Asdtes 37(34%) 
Splenomegaly 23(21%) 
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cryptogenic (n=3). Serological markers of hepatitis B infection (HBsAg or HBcAb alone) were present 
in 29% (n=32) of patients; HBsAg in 9% (n=10) and HBcAb alone in 22% (n=22). Hepatitis B-related 
cirrhosis was present in 19 cases. The other 13 cases included one patient with HBsAg and no 
cirrhosis, and 12 cases with HBcAb alone. Insufficient normal liýer was available'to establish the 
presence or absence of cirrhosis in 6 of these cases and the other 5 cases were cirrhotic but the 
aetiology was considered to be haernochromatosis (n=1), alcohol (n=2), and autoimmune chronic 
hepatitis (n = 2) based on a combination of serum biochemistry and immunology, and histological 
findings. 
Cirrhotic patients were more likely to be male than non-cirrhotic patients and had a worse prognosis 
(Table 2.3.3). No fibrolamellar turnours, which occur characteristically in predominantly younger 
non-cirrhotic females and have a better prognosis, were seen in this study. 
2.3.4 Investigations 
The median haemoglobin concentration was 12.7g/dl and only 2 patients had an haematocrit of 
greater than 0.5 . The prothrombin time was prolonged in 54% of patients but was prolonged to 
greater than 4 seconds above normal in only 9%. Most patients had abnormal liver function tests but 
no pattern (hepatitic or cholestatic) predominated (Table 23.4). Hypoglycaemia at presentation was 
only diagnosed in 2 patients. Both patients had symptomatic hypoglycaemia with a low random 
serum glucose level. Fasting glucose levels were not performed on any of the patients in the study. 
27 patients were known to be cirrhotic at diagnosis and thus potential candidates for c(-feto protein 
(c(-FP) screening at six monthly intervals to detect early treatable turnours. Of these patients, 22 had A 
raised a-FP and could therefore have been diagnosed through screening. However eleven of this 
group had not received screening and 4 patients had only had the occasional a-FI' level measured; 
the diagnosis of HCC in these patients was made because of symptoms. Thus only 7 patients were 
asymptornatic and diagnosed as having HCC through screening. At diagnosis 13% (n=14) patients 
had an a-FP of less than 10ng/ml. In the remaining patients the a-FP levels were between 10- 
200ng/mI in 24%, 200-500ng/ml in 16% or greater than 5OOng/ml in 47%. 
Ultrasound scanning was performed in 83% (n=gl) of cases, CT scans in 55% (n=60) and angiography 
in 48%(n=53). The ultrasound was abnormal in 93% (n=85) of cases showing either a single hepatic 
mass (n=43), diffuse hepatic infiltration (n=15) or multiple tumour nodules (n=27). All CT scans were 
abnormal with a single defined tumour mass reported in 22 cases and multiple tumour nodules 
reported in 38 cases. 
2.3.5. Staging 
Patients were staged according to Okuda (Okuda et al, 1986) at diagnosis on the basis of four adverse 
prognostic features (bilirubin > 50mmol/l, albumin < 30g/l, presence of ascites and tumour size 
>50% of liver bulk on an anterior-posterior view of a colloid isotope scan). Patients in group 1 had 
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Table 233: Comparison of clinical features in cirrhotic and non-cirrhotic patients. 
Clinical features CuThotic (n=75) Non-cirffiotic (n =24)' 
Median age (yrs) 64 62 
Malesex 769o' 487o 
HBsAgpositive 1217o 47o 
aFP>, 5001U/I 401/o 
Median survival (weeks) 9 16 
21 
Tabk 23.4: Presenting biochanical and hamutological investigations. 
Test (units) Mean Range % abnormal Nozmal zange 
Haernoglobin(g/dl) 12.7 6.6-182 31 14-17(male) 
12-15.5 (female) 
White cell count (xlCPA) 92 2.7-44 29 4-11 
Platelets (xlO9/dl) 242 21-677 24 15(Y350 
Prothrombin time (see) 16 11-65 82 15 
Bilirubin (pmol/1) 51 3-550 60 < 17 
Aspartate transaminase 
(IU/I) 119 15-549 79 <40 
Alkaline phosphatase 
GUA) 354 30-1608 82 <130 
I Albumin (g/1) 34 22-45 
1 14 130-50 
za 
none of these features, those in group 2 had one or two of these features and those in group 3, three 
or four. In this study 23% were stage 1,63% stage 2 and 13% stage 3. 
The size of the tumour was demonstrated by radiology in 63 cases and was greater than 5cm in 79%. 
The tumour was considered multifocal. in 46% (n=51). In the 59 cases considered to have unifocal 
disease the turnour was limited to the right lobe in 51 and the left lobe in only 8 cases. It is likely that 
these results underestimate the extent of liver involvement by HCC as the findings are obtained from 
a retrospective review of radiology reports of procedures performed by different radiologists. 
2.3.6 Treatment 
Fourteen patients were considered to have surgically resectable disease and underwent laparotomy. 
However, at operation curative resection was not possible in any of these. Nine patients 
subsequently had adjuvent chemotherapy. 27 (25%) patients were treated conservatively. The other 
69 patients received chemotherapy with intrahepatic adriamycin /lipiodol (n= 36) or intravenous 
chemotherapy, which included adriamycin, CB3717 or VP16 with 5 -flurouracil. 
2.3.7 Prognosis 
The overall median survival was 13.1 weeks. Dependant factors affecting survival included age, 
Okuda stage and treatment. The median survival of patients aged over 65 years was 105 weeks 
compared to 18.5 weeks for those under 65 years (p=0.02). The median survival of Okuda stage 1 
patients was 16.5 weeks, while that for Okuda stage 2 was 13 weeks and for stage 3 patients was 7.6 
weeks (p=0.03). Due to the small numbers treated with surgery alone and surgery combined with 
chemotherapy these groups were combined with chemotherapy when analysing survival. The 
median survival of those treated conservatively was 6.4 weeks compared to a median survival of 15.1 
weeks in the treatment group (p=0.008). Since the older age group were more likely to be treated 
conservatively the interaction of age group (<65 or >65 years) and treatment (conservative v any 
treatment) was examined by a Cox regression model (Cox, 1972). Using this model the adverse effect 
on survival of age group disappears when adjusted for treatment (Table 2.3-7). 
2.4 Discussion 
This study confirms the association of HCC with older age, male sex, hepatitis B viral (HBV) 
infection, and cirrhosis which are believed to be important aetiological factors in 
hepatocarcinogenesis. Increasing age and male sex are universal risk factors world-wide although the 
median age of onset of HCC is 10 years lower in high incidence areas such as South Africa (Kew and 
Geddes, 1982). 
Serological markers of hepatitis B infection however were only present in 29% of this British patient 
population which contrasts with the high prevalence of HBV in HCC patients from high incidence 
areas (reviewed Chapter 1). These values may underestimate the role of the virus in HCC as HBV 
DNA has also been detected in tumour liver and surrounding cirrhotic liver of patients with HCC in 
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Table 23.7. Effect of age group, Okuda stage and treatment on surt*W. Cox regression model. 
Dependant variable is surtdbal, independant variables are age group (<65,65 or greater), 
Okuda stage (IIIJI) and treatment (conservative, any treatment). 
Variable Coeffident Standard B/SE Reliable risk Confidence 
(9) error (SE) MR) interval 
95% for RR 
Modell 
Agegroup 0.197 0.208 2383 1.643 1.09-2.41 
Mode12 
Okuda 0.520 0.221 2357 1.68 1.09-259 
Agegmu 0432 0.210 201 201 1.01-230 
Model3 
Treatment 1M 0.258 4.654 3.33 Z01-553 
Age group 0.223 1.061 1.26 0.82-196 
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the absence of serological HBV markers (Paterlini et al, 1993). Other environmental agents that have 
been implicated in the pathogenesis of HCC include alcohol and hepatitis C. Alcohol is only 
associated with an approximately 4 fold increased risk of developing HCC (Vecchia et al, 1988 
Poynard et al, 1991). It is, therefore, more likely that it acts as a cofactor with other hepatocarcinogens 
(reviewed by Bassendine, 
' 
1986). Hepatitis C infection is related to HCC but the prevalence of 
infection in Britain is low and is unlikely to prove a major contributory factor; this is in contrast to 
countries in Southern Europe (Sirchia et al, 1989). Thus other, as yet unrecognised, environmental 
toxins need to be considered as potential hepatocarcinogens in Northern Europe. The finding of 
cirrhosis in 76% of patients with HCC is in agreement with the high incidence of cirrhosis associated 
with these turnours world-wide (reviewed Chapter 1). 
In this study symptoms at presentation were generally nonspecific which is similar to findings 
reported from North America (Chlebowski Ct al, '1984) and the Far East (Liver Cancer Study Group 
Of Japan, 1987). The presence of abdominal pain, however, present in 69%, should arouse suspicion 
of a developing HCC in an at risk patient. Interestingly paraneoplastic phenomena, such as 
hypoglycaernia and polycythaemia, were rare. This contrasts with reports of hypoglycaemia in up to 
30% of patients with HCC in high incidence areas (McFadzean and Tse Tse, 1956). The overall picture 
of HCC in Britain is of a turnour that presents late and often on the background of undiagnosed 
cirrhosis. This is exemplified by the finding of multifocal turnour in 46% of patients in this study 
with 80% of turnours over 5 cm in diameter. Moreover, this study probably underestimates the extent 
of disease as many of these assessments was made only on the basis of ultrasound and isotope liver 
scans. The recent availability of lipiodal angiography, lipiodal being retained by the tumour and 
detectable on a CT scan performed two weeks after angiography, has led to an increase in the 
detection rate for multifocal turnours. 
The overall survival of patients in this series was only 3 months. This is comparable with survival 
rates reported from Europe (Calvert et al, 1990) and for untreated patients from Japan (Nagasue et al, 
1984). However, overall the prognosis of HCC is much better in Japan and this probably reflects the 
fact that 50% of turnours are operable at diagnosis (Liver Cancer Study Group Of Japan, 1987). In 
contrast, all turnours in this study were unresectable, based preoperatively on the presence of 
multifocal turnour or tumour greater than 5cm, or on operative findings. The reason for the late 
presentation and poor prognosis of HCC in Western countries is still unclear. One factor may relate 
to the presence of cirrhosis which is an adverse prognostic indicator in low incidence areas (Melia et 
a], 1984; Smalley et al, 1988) in contrast to high incidence areas where the presence or absence of 
cirrhosis has no effect on the course of the disease (Kew and Geddes, 1982, Nagasue et al, 1984). 
Another factor contributing to the early detection of HCC in Japan has been the introduction of 
screening for high risk cirrhotics patients (Tanaka et at, 1987). Screening has been shown to improve 
the percentage of resectable turnours and hence the prognosis In HCC (Liver Cancer Study Group of 
Japan, 1990). However a recent study from Italy failed to show any increase in the rate of detection of 
potentially curable turnours using a-FP and realtime ultrasound screening in known cirrhotics in a 
low incidence area ( Colombo et al, 1991). An important limitation to screening in Britain is the 
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finding that only 25% of patients were known to be cirrhotic at the time of diagnosis, which is much 
lower than that reported from Southern Europe and Japan (77% and 54% respectively). Consequently 
a significant proportion of British patients with HCC would not have have been candidates for 
screening. 
HCC in Britain differs from that in high prevalence areas, such as China, in that it is less likely to be 
associated with hepatitis B infection or aflatoxin exposure, and more likely to present at an advanced 
stage. In contrast cirrhosis appears to be an important risk factor for HCC worldwide. This clinical 
picture suggests the existence of different (but overlapping) mechanisms of hepatocarcinogenesis 
between Britain and areas of high tumour prevalence. Studies outlined in subsequent chapters of 
this thesis concentrate firstly, on why cirrhosis may be a risk factor for HCC and secondly, on factors 
potentially contributing to the aggressive growth of these turnours in northern Britain. Aflatoxin and 
hepatitis B appear unikely to play a major role in hepatocarcinogenesis in Britain. It is possible that 
DNA damage in cirrhotic tissue may be induced by other environmental carcinogens, in particular 
the ubiquitous alkylating agents. The hypothesis that deficient repair of such DNA injury, by the 
DNA repair enzyme 06-methylguanine -DNA methyltransferase, occurs in cirrhosis predisposing to 
the development of HCC is explored further. 
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2.5 Summary 
Clinical Features Of HCC In North-East England 
Age (median) 65 yrs 
Male: female 7: 3 
Cirrhotic -known at 25% 
presentation 
Cirrhotic -after investigation 76% 
Hepatitis B markers 29% 
Stage at presentation >5cm and multifocal 
Survival (median) 13.1 weeks 
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Chapter 3 
DNA Repair By , 06. methylguanine - DNA methyltra n sfe rase 
In Cirrhosis 
34 
3.1 Introduction 
Despite the well known association between cirrhosis and HCC the role of cirrhosis in the 
development of HCC remains unknown. The possibility that deficiency in DNA repair mechanisms 
in cirrhotic tissue may make it more susceptible to damage by environmental carcinogens has not 
previously been addressed. 
&- methylguanine - DNA methyltransferase OMT) repairs the promutagenic DNA lesion 06- 
methylguanine, produced by environmental alkylating agents, by removing the methyl group and 
transferring it to its own specific cysteine residue (review ed Pegg et al, 1990). As a result it becomes 
inactivated and is not regenerated, thus in the absence of new enzyme synthesis the total cellular 
level of &-MT represents the DNA repair capacity of the cell for this promutagenic lesion (Foote et 
al, 1980; Pegg et al, 1983). &-MT appears to require no cofactors and has an optimum pH of about 
7.8-8.5 (Pegg et al, 1983; Bouldon et al, 1987). The rate of repair is reduced by unmethylated DNA 
probably because of binding of &-MT to this DNA (Bouldon et al, 1987). It is also strongly inhibited 
by metal ions such as Cu2'. Hg2',, Zn2" (Scicchitano et al, 1987, Bhattacharyya et al, 1988b). Such 
inactivation can be inhibited by dithiothreitol which is consistent with the reaction of these metals 
with the thiol group of the methyl acceptor cysteine. Dithiothreitol is therefore added to buffers in 
assays of 06-MT to reduce enzyme loss. Several methods have been developed to measure the level 
of 0'-Nff in tissue extracts (reviewed by D'Incalci et al, 1988). These can be divided into two groups, 
(a) indirect assays, which measure the disappearance of 06-methylguanine from methylated DNA 
after reaction with the &-MT containing cell extract of interest, and (b) direct assays, which measure 
the transfer of radiolabelled methyl groups from a prepared &-methylguanine substrate to the 
protein fraction of an 06-MT-containing cell extract. In the indirect assays, 06-methylguanine 
removal is monitored by HPLC or immunoassay of the acid hydrolysed DNA reaction product. In 
the direct assays, radiolabelled methylated protein is separated from the repaired DNA by either 
proteinase solubilisation of protein, or removal of DNA by acid hydrolysis and washing with the 
radiolabelled protein being retained on glass filters. 
The level of 06-MT in normal human liver tissue has previously been measured in several small 
studies (Table 3.1). These have shown that liver contains higher amounts of the enzyme than other 
human tissues but have also demonstrated that there is substantial inter-individual variation as has 
been described for other tissues (Table 3.1). Measurement of 06-MT in any tissue is made difficult by 
the requirement for large tissue samples because of the low enzyme abundance and relative 
instability. 06-MT has therefore been hitherto quantified in the liver using tissue obtained at 
operation rather than from percutaneous liver biopsies; this is reflected in the small numbers of 
patients studied to date. There are no previous studies looking at the DNA repair enzyme in cirrhotic 
liver or non-cirrhotic diseased liver. 
The initial aim of this study was to establish reliable methodology for measuring the enzyme in 
small human liver biopsy specimens (5-15mg). 06-MT was then measured in biopsy samples from 
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Table 3.1: Mean levels of 06-MT reported in nonnal human liver. 
n ol-mr 
(fmo]Vmg protein) 
Ra%ye 
(n-fold) 
Refmnce 
10 873 45 Pegg et al, 1982 
9 1070 7.8 Mymes et al, 1983 
5 394 2-3 Hall et a], 1985 
8 480 (55*) 2-3 Gerson et al, 198 5 
cf-mr exprmsed as finoi /pg DNA 
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normal, and diseased (non-cirrhotic and cirrhotic) liver in order to establish whether DNA repair by 
&-MT was impaired in cirrhotic liver. It had previously been reported that lymphocyte 06 MT levels 
correlated with enzyme levels in gastric tissue (Kyrtopoulos et al, 1990). Lymphocyte levels were, 
therefore, also assayed and compared to liver levels to assess whether they could act at a surrogate 
marker for levels in normal and diseased liver. 
3.2 Clinical material and methods 
3.2.1 Development of assay for liver biopsies 
Reagents 
Buffer A 5OmM Tris (Gibco/BRL)/HCI (BDH)(pH 8.3), 0.5mM EDTA 
(BDH), lmM dithiothreitol (Calbiochem) 
CTAB 3% (w/v) cetyltrimethylammoniurn bromide (BDH, laboratory 
reagent grade) 
EDTAIDNA 8OmM EDTA (BDH) /HCI (pH6.0), 200pg calf thymus DNA 
(Sigma), 
Proteinase K ImM CaC12 (BDH), 50pg proteinase K (Sigma type Xl) 
Unless indicated all reagents, were of AnalaR grade or highest purity obtainable. 
Tissue 
Three different sources of normal human liver were used: (1) caderveric renal transplant donors 
(samples stored at -80*C for less than 1 year), (2) patients undergoing cholecystectomy (samples 
stored at -801C for 5 years), (3) post mortern liver obtained within 4 hours of death. Tissue from 
patients undergoing cholecystectomy which had been repeatedly thawed and refrozen was also 
available for study. 
Tissue extraction 
Extracts of liver were prepared by homogenising 5-15mg of tissue in 1ml of Buffer A using a micro- 
homogenizer (Omni, USA). Working on ice as far as possible, homogenisation was achieved using 2 
x5 second sessions separated by a 30 second interval. The amount of tissue used was estimated by 
comparing it's size with previously weighed biopsy samples, as preliminary work had shown that 
direct weighing of the tissue resulted in loss of enzyme activity, presumably caused by tissue 
thawing. 10pl of homogenate was removed for assay and the remaining homogenate was centrifuged 
at 15000xg for 20 min at 41C. The supernatant (designated 'tissue extract') was removed and used 
immediately in the assay. The remaining pellet was resuspended by homogenisation in 400pl of 
buffer A and assayed to ascertain enzyme extraction efficiency. During the procedure all tissues and 
extracts were kept at VC on ice. The enzyme assay was always performed immediately following 
extract preparation. 
Enzyme assay 
&-MT levels were determined using a sensitive direct enzyme assay ( Major et al, 1991). Tissue 
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extracts were diluted to a final volume of 200pl and then incubated with 10pl of substrate DNA, calf 
thymus DNA which had been produced to contain tritiated methyl groups at the &position of 
guanine (4000-5000 dpm). Extract dilutions were made using 2- 50PI of extract made up to 200PI 
using Buffer A, each test dilution was performed in triplicate. Incubation of substrate and extract was 
performed at 37*C for 90 minutes, conditions which allowed the repair process to go to completion. 
The reaction was then stopped by the addition of 300pl of DNA/EDTA. Precipitation of residual 
substrate DNA and digestion of any R-11-methylated protein in association with DNA was achieved 
by the addition of 200pl of CTAB and 10pl of proteinase K respectively, then vigorously mixing and 
incubating tests and controls at 37*C for 60 minutes, followed by centrifugation at 13,000xg for 20 
min to pellet the DNA. rHI-methyl groups associated with the enzyme were determined in a 650pl 
sample of the resulting supernatant, by its mixture with 4mls of Pico-Aqua scintillation cocktail 
(Canberra-Packard) and measurement of radioactivity in a scintillation counter (Canberra-Packard 
2500TR). An enzyme dilution curve, prepared using a fixed amount of substate, was constructed for 
each extract. The molar amount of enzyme was then calculated from the linear portion of the curve 
using knowledge of the specific radioactivity of the M-methylated substrate (17.9 Ci/mmol or 40 x 
103 dpm/pmol) and the stoichiometric nature of this DNA repair reaction i. e. one enzyme molecule 
reacts with one substrate molecule, and the enzyme has one active site (Figure 3.2.1). 
DNA and protein estimation 
Protein content of tissue extracts was determined by the Coomassie G-250 dye-binding method of 
Bradford using a BioRad protein assay kit and bovine serum albumin (Sigma) as the calibrating 
protein (Bradford, 1976). DNA was measured by fluorescence using a TK-100 fluorometer (Hoefer 
Scientific Instruments), Hoechst dye 33258 at O. lpg/ml and calf thymus DNA as the standard 
(Cesarone et al, 1979). 06-MT levels were expressed in two ways: amount per total extract DNA and 
per total extract protein. 
3.2.2 Assay of 06-MT In liver and lymphocytes 
Case material 
Forty eight patients admitted to Medical Unit 1, Freeman Hospital, Newcastle upon Tyne, for 
investigation and treatment of liver disease, were studied. All diagnoses were based on a 
combination of clinical, biochemical, serological and histological findings. Patients were classified as 
either having cirrhosis (n=23), non-cirrhotic liver disease (n= 19) or normal liver histology (n= 6); 
(Table 3.2.2). Those patients with normal liver histology had abnormalities in liver function tests 
prior to biopsy which subsequently returned to normal. Liver biopsy material upon collection was 
immediately snap- frozen in liquid nitrogen and stored at -80*C. Whole blood, for lymphocyte 
isolation, was taken from 30 patients at the same time as'liver biopsy and from a further 11 healthy 
controls who had not had liver biopsies. 
Isolation of lymphocytes and enzyme extraction 
20mls of whole blood was collected into heparinised tubes. Isolation of lymphocytes was performed 
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Figure 3.2.1: Enzyme assay, (A) Schematic representation of the enzyme assay 
illustrating the stochiometric reaction between d -MT and methylated DIVA 
substrate. The SH group represents the cysteine residue at the active site of the 
enzyme. (B) 7]jpkal enzyme dilution curve showing radiolabelled en; yme in the 
extract as a function of extract volume following reaction with a fixed amount of 
substrate; at higher extract volumes the substrate concentration becomes limiting. 
A ctivihi is derived from the linear portion of the curve. 
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Table322- C&kaldetails on 48palkntsfrom whom kner biopsy t&we uasami7ablefromfor 
01-mTawy. 
Cirrhosis Non-cirrhotic liver 
disease 
Normal 
n 23 '19 6 
Age (yrsr M 
(a75) 
ý 53 
(24-7Z 
51 
(30-62) 
Male: Female 149 145 42 
Diagnosis Alooholic (n--1 1) Alcoholic steatosis (n---13) 
Cryptogertic (n=5) Ich Ropathic steatosis (n=6) 
Chronic acdve hepatitis (n=l) 
Hep fitis C (n; -4) 
Primmy bý chThosis (n=2) 
* mean (mnge) 
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by density-gradient centrifugation through Lymphoprep Wycomed AS, Oslo) according to the 
manufacturer's instructions. Briefly, 10mls of whole blood was layered onto 6 mls of Lymphoprep 
and centrifuged at 15000 rpm for 20 minutes. The lymphocyte band was carefully removed using a 
glass pasteur pipette and washed by centrifugation at 1800 rpm for 15 minutes in 10mls of phosphate 
buffered saline (PBS), pH 7.4 (Sigma). The pelleted lymphocytes were similarly washed again but 
using a5 minute centrifugation time. This pellet was resuspended in 6 mls of PBS and a 10pI sample 
was removed for lymphocyte counting using a haemocytometer. Finally, the lymphocytes were 
pelleted by centrifugation at 1800 rpm for a further 5 minutes, the supernatant removed and the 
pellets stored frozen at -80*C. 
Lymphocyte extracts were prepared in the same way as liver extracts except that homogenisation 
was performed in 6OOpI of Buffer A made 5OmM with NaCI (Buffer B) to achieve extraction efficiency 
equivalent to that obtained with liver tissue (personal communication; Dr K Guo, Medical Molecular 
Biology Group, University of Newcastle upon Tyne). 
Statistics 
Analysis of variance (ANOVA; F-test) was used to compare differences in tissue 06-MT levels 
between the 3 different groups of patients. Mean enzyme levels were compared between cirrhotic 
patients and either non-cirrhotic liver disease patients or individuals with normal liver histology, 
using a Rest. Lymphocyte and liver levels of O'LMT from the same patients were compared by linear 
regression analysis. Calculations were made using "Statview 512+" software on an Apple Macintosh 
computer. 
3.3 Results 
3.3.1 Preparation and storage of human tissue and cell extracts containing 00 -MT 
Human liver sample storage 
No 06-MT was present in post mortern liver biopsies, suggesting that the enzyme may have been 
inactivated as a result of proteolytic digestion. Optimal tissue storage, therefore, necessitated 
immediate snap-freezing in liquid nitrogen and storage at -80*C. In this manner liver could be stored 
for 1 year without appreciable loss of activity. Normal liver which had been subjected to frequent 
episodes of thawing and refreezing had significantly lower levels of &-MT than optimally stored 
tissue (mean±SEM fmol/mg protein of 649: t4O vs; 2322: tl10; p= 0.0001) as did tissue stored for a 
prolonged period (5 years) at -80T (573±46 vs 2322±110; p= 0.0001). The inter-assay precision 
(expressed as a coefficient of variation) for optimally stored tissue was 11%, compared to that for 
liver stored for a prolonged period of 30% and 24% for liver thawed repeatedly (Figure 3.3.1a). 
Liver sample handling and enzyme extraction 
Following removal from -80"C storage weighing of tissue at room temperature prior to enzyme 
extraction resulted in loss of O'LMT activity. Consequently, liver biopsy tissue could not be routinely 
weighed, and enzyme levels are expressed in relation to measured tissue protein and DNA content, 
but not wet weight of tissue. However the wet weight of normal liver did 
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06 Figure 3.3.1a: - MT levels measured in extracts prepared fiom normal liver 
stored at (A) -80'C for less than 1 year, (B) at -801C for 5 years, (C) 
defrosted1refrozen repeatedly prior to extraction and enzyme assay. Mean level 
(-±SEM ) of multiple biopsies fiom same liver sample, assayed on separate days is 
indicated by the horizontal bars. Me mean (±SD ) in finolft protein was (A) 
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correlate with protein in liver extracts (n = 12 ; r= 0.921; p=0.0001), the mean being 71 mg protein 
/gram wet tissue. This value is similar to that previously reported by others for normal liver (Bielicki 
et al, 1990 ; Tuchman et al, 1990) and indicates that extracted protein levels reflect the amount of 
tissue used to produce the extract despite the fact that the protein content only accounts for about 
7% of tissue weight. 
Effect of storage of extracts prior to assay on enzyme levels 
Incubation of liver extracts at increasing temperatures in the range of 0 to 37*C for up to 5 hours 
prior to enzyme assay resulted in appreciable loss of 06-MT which was progressive with time and 
temperature (Figure 3.3.1b). This finding is in accordance with Major et al who showed in human 
spleen extracts that while the enzyme was labile to high temperature this effect was not observed 
following the addition of substrate DNA which stabilised the enzyme (Major et al, 1991). Extract 
handling conditions that preserved enzyme activity prior to enzyme assay were found to be keeping 
extracts at O*C on ice after their preparation, assaying for &-MT as soon as possible , then storing 
remaining extract at -800C. Prolonged storage of these extracts at -800C still resulted in loss of 06-MT, 
with only 65% of the enzyme remaining at 2 months. Such enzyme instability was not, however, seen 
with human lymphocyte extracts prepared and stored in a similar manner (Table 3.3.1 a). 
Extraction efficiency 
As 06-MT is a DNA repair enzyme it can be expected to have a predominantly nuclear distribution. 
Tissue hornogenates were, therefore, made under conditions which promote whole cell disruption, 
namely freeze/thawing, the use of hypotonic buffer and blending using a rotating metal blade. 
Under these conditions nuclear enzyme should pass into the supernatant. The efficiency of this 
process was confirmed by the finding of 90% of the enzyme, present in the homogenate, in the 
supernatant with only 10% in the residual pellet (Table 3.3.1b). 
3.3.2 Variation In 06-MT levels 
With liver tissue stored at -80T, extraction followed by immediate enzyme assay gave an intra- 
assay variation in 06-MT levels of 10-14% (Table 3.3.2). The inter-assay variation, a measure of day 
to day variability, was 11 
3.3.3 0'-MT In liver biopsies and lymphocytes 
&-MT levels were measured in liver biopsies from cirrhotic (n=23), non-cirrhotic diseased liver 
(n=19) and normal liver (n=6). There was a highly significant difference in enzyme levels expressed 
in relation to total extract protein, between the 3 groups of patients (F = 28; p=0.0001). The mean 
level of 06-MT was significantly lower in the cirrhotic group when compared to the non-cirrhotic 
liver disease (p = 0.0001) and normal groups (p = 0.0001). Lymphocyte levels of &-MT, however, did 
not differ significantly between any of the patient groups (F = 0.29; p=0.75), and were generally 
higher than liver levels in all patient groups when expressed in relation to total extract protein and 
lower when expressed in relation to total extract DNA (Table 3.3.3). 
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Figure 3.3.1. b: Effect of temperature on enzyme activity. Liver extracts were 
preincubated, immediately following enzyme extraction, at different temperatures 
for 0-5 hours prior to 06_ MT assay. Enzyme levels were expressed as a 
percentage of activity present at time 0. 
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Time (hours) 
Table 3.3.1a. - Effect oftrolonged storage of normal human liver and I . Wnphoryte extracts 
at -80'C on 01-MTachvity. &-MT uns assayed in hver and lymphocyte extractsfrom 
tuv patients immed, 67telyfollouing extract preparatim (inithd 06 -MV and then follouing 
2 to 8 weekpe7iods ofstorage. 
Duration of % of initial 06-Mr 
extract 
storage at Liver extract Lymphocyte extract 
-800C 
-- - (Weeks) Patient 1 [ Patient 2 Patient 1 
- Patient 2 
1- 
0 100 100 100 100 
2 75 100 100 100 
4 65 95 100 100 
8 65 86 100 100 
Table 33.1b. - Efflciency of 06'-AlTextradionfrom nornzalhunun liver on three consecutive 
days. 06-MT was measured in the supernatant(extract) and residual pellet following 
centrifugation of the homogenate. The total amount of &-MTfollowing cell disruption, 
ref7ected in the homogenate levels, is cmnpared wi? h the supenzatant and residual pellet. Me 
% ofenz yne in the supffnatant rej? ects the e; &action efficiency. 
Tissue fiaction 06-MT (finol) 
Dayl Day2 Day3 
Homogenate 404(100%) 828(100%) 390(100%) 
Supematant (extract) 375(93%) 746(90%) 341(87%) 
Residual Pellet 35(7%) 
1 86(10%) 3900%) 
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Table 3.3.2: In tra-assay variation in liver extract 06-MT levels prepared from normal 
liver on three consecutive days. Extracts were prepared from 4 samples from the same 
liver on each day. 7he intra-assay variation is expressed as a coefficient of variation. 
Day Number 
Of 
samples 
Mean 
(finol/mg 
protein) 
SD SEM Coefficient of 
variation 
1 4 2643 261 131 10% 
2 4 2111 294 148 14% 
13 4 
2235 293 146 13% 
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Table 3.33., 06 -MT in liver and lymphocyte extracts preparedfrom different patient 
groups. Enzyme levels from patients with cirrhosis, non-czir6otic liver disease and 
normal fiver kistology are expressed as a mean (SEM) and related to both total cellular 
protein and total cellular DNA. 
Normal Non-cirrhotic 
diseased liver 
cirrhotic 
Liver 06-Mr (n = 6) (n = 19) (n = 23) 
ftnol /pg DNA 989 (111) 870 (68) 540 (57) 
frnol / mg protein 2164 (270) 1823 (75) 1016 (87) 
Lymphocyte 06-MT (n = 15) (n = 15) (n = 11) 
fmol /pg DNA 1138 (92) 1449 (128) 1193 (74) 
fmol / mg protein 943 (71) 985 (105) 872 (137) 
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Levels of 06-MT were determined both in relation to total extract DNA and total extract protein as 
the protein to DNA ratio differs between lymphocyte and liver extracts. With regard to solid tissue, 
DNA measurement will provide a more accurate reflection of cellularity thus enabling direct 
comparison with lymphocyte enzyme levels. A significant difference in liver 06-MT levels expressed 
in relation to extract DNA was also evident between the 3 patient groups (F = 9.91; p=0.0003), with 
mean levels of 06-MT being significantly lower in cirrhotic tissue than either non-cirrhotic diseased 
liver (p = 0.0006) or normal liver (p = 0.01). Lymphocyte levels of &-MT expressed per extract DNA 
did not differ significantly different between the 3 groups (F = 2.64; p=0.085). 
When expressed in relation to total extract protein, there was a two- to three-fold inter-individual 
variation in &-MT levels in normal and non-cirrhotic liver, and a seven-fold variation in cirrhotic 
livers. A similar variation was also seen between the same groups (2,3 and 6.5-fold, respectively) 
when 06-W was expressed in relation to total extract DNA (Figure 3.3.3). Lymphocyte levels in all 
three groups displayed three- to four-fold interindividual variation when expressed in relation to 
either total extract protein or DNA. 
3.3.4 Relationship of 06-MT levels between liver and lymphocyte extracts 
Overall comparison of 06-MT levels (expressed in relation to extract DNA) between matched 
lymphocytes and liver extracts prepared from all three patient groups revealed no significant 
correlation (r = 0.259, p=0.159, n=30). This lack of correlation extended to the subgroups of patients 
considered separately; non-cirrhotic liver disease (r = 0.35, p=0.2, n=15) and cirrhotic patients (r = 
0.27, p=0.42, n=11). This comparison could not be made with matched normal liver and 
lymphocytes due to low sample number (n=4). A similar lack of correlation was also observed when 
06-MT levels were expressed in relation to extractable protein(Figure 3.34 
3.4 Discussion 
The feasibility of measuring 06-MT in small gastric biopsies with an inter-assay precision of *10% 
has previously been reported (Dyke et al, 1990). This study shows that 06-MT can also be measured 
in human liver biopsies with a similar inter-assay variation of 11%. Instability of 06-MT is well 
Tecognised but the hepatic enzyme appears to be particularly labile. Prolonged storage of liver tissue 
and extracts at -80*C resulted in enzyme loss a phenomenon which is not seen with lymphocyte 
pellets or extracts. It is therefore possible that part of the variation in liver enzyme levels reported in 
the literature (Table 3.1a) is an artefact due to differences in tissue handling with variable loss of 
enzyme activity occuring during the time from biopsy to enzyme assay. This is supported by the 
much smaller 2-3 fold inter-individual variation observed in normal liver in this study, when 
compared to previous studies, where enzyme handling conditions had been optimised. 
Similar inter-individual variation also occurs in other normal tissues. Differences range from 14 fold 
in stomach (Dyke et al, 1990), 10 fold in the colon to 4 fold in T lymphocytes (Strauss, 1990) and the 
brain (Wiestler et A 1984). The contributions made by genetic and environmental factors to this 
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variation has yet to be elucidated. Variations in &-MT levels within a tissue not only varies between 
individuals but also varies in the same individual with time. This cannot be quantitated in the liver 
because of the difficulties in obtaining multiple biopsy specimens. However lymphocyte levels 
measured 4 times over the course of a year differ by only 25% (intra-individual variation), much less 
than the 7 fold inter-individual variation seen in these cells (Sagher et al, 1988; Sagher et al 1989). 
Thus, if lymphocytes are representative of liver tissue intra-individual variation is unlikely to be a 
major contributory factor in liver tissue variability. The possibility that the 2-3 fold inter-individual 
variation seen in normal liver may be one factor determining the susceptibility of non-cirrhotic liver 
to the development of HCC is a hypothesis which deserves further evaluation. 
Human susceptibility to carcinogens, whether acquired or inherited, appears to depend on several 
factors. From studies in animals susceptibility to nitrosamines might be expected to depend on the 
balance between 4 factors which together determine the extent of replication of alkylated DNA; (1) 
the ability of the tissue to metabolise nitrosamines to carcinogenic intermediates that alkylate DNA at 
the &position of guanine, (2) the extent of adduct formation at the &position of guanine, (3) the 
rate of removal of the & alkyl adduct which will depend on the tissue level of 06-MT and (4) the 
extent of DNA replication which occurs during a critical period when the adduct is present 
(Craddock, 1986). On this basis, cirrhotic liver tissue would be expected to be susceptible to 
nitrosamine-induced carcinogenesis; the liver is an important site for nitrosamine metabolism and 
cirrhosis is characterised by increased liver cell proliferation and DNA synthesis. The present finding 
of deficient repair of 06-methylguanine in cirrhotic liver, as a result of lowered 06 MT levels, 
provides a further reason for this tissue being at particular risk of malignant transformation 
following exposure to alkylating agents. 
Although &-MT levels were significantly lower in cirrhotic livers as a group compared to non- 
cirrhotic livers there was a 7-fold inter-individual variation in enzyme within cirrhotic tissue. This 
variation was greater than that seen in normal liver and raises the possibility that a combination of 
both genetic and acquired factors determines 06-NIT levels in disease. The relatively large inter- 
individual variation of &LMT levels in cirrhotic tissue suggests that not all patients with cirrhosis 
will carry the same risk of developing hepatocellular carcinoma. This is consistent with cirrhosis of 
different aetiologies, displaying a characteristic risk for the development of HCC (Bassendine, 1987). 
Larger studies are required to assess whether 06-MT levels are lowest in those forms of cirrhosis 
associated with a higher risk of developing HCC, such as those due to haemochromatosis, chronic 
hepatitis B and C infection (Kew et al, 1990). 
Epidemiological studies indicate that alcohol is associated with a 4-fold increased risk of developing 
HCC (Hardell et al, 1984). It is thought most likely to act as a co-carcinogen with other factors such as 
cirrhosis and hepatitis B infection (reviewed Bassendine, 1986). It is, therefore, of interest that both 
alcohol and its reactive metabolite acetaldehyde appear to inhibit both rat and human 06-MT in vitro 
(Espina et al, 1988). Moreover, in rodents chronic alcohol consumption is associated with a reduction 
in liver &-MT levels (Garro et al, 1986). These studies have not been extended to alcoholic liver 
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disease in man. Although, in this study no difference in enzyme activity was seen between those 
with alcohol- and non-alcohol-related disease in either the non-cirrhotic or cirrhotic groups, a 
relationship between chronic alcohol abuse and impaired DNA repair cannot be excluded as the 
numbers in each group were small. 
Old age and male sex are also important risk factors for HCC (Goodwin et al, 1986; lhde et al, 1974). 
The effect of age on DNA repair by 06-MT in normal human liver is unknown although fetal rodent 
liver has been shown to have lower levels of Cf-MT than adult tissue (Krokan et al, 1983). Once adult 
enzyme levels have been reached in rats there is then a progressive fall in activity with further 
increasing age (Pardini et al, 1992). Only one small study has attempted to correlate age with 06-TVff 
levels in man, and no correlation was seen between increasing age and enzyme levels in the 19 
patients, over 75 years, studied (Edwards et al, 1989). In the light of the inter-individual variation in 
levels of this enzyme large population studies with repeated measurements of enzyme levels would 
be required to assess the effect of age on DNA repair by 06-MT. Comprehensive studies looking at 
the effects of age, sex and aetiology of cirrhosis on 06-MT levels in cirrhotic tissue are now feasible as 
a result of the development in this study of a reproducible method for the measurement of 06-Nff 
levels in liver biopsy samples. 
The previously described correlation between gastric mucosa 06-MT levels and levels in circulating 
lymphocytes raised the possibility that lymphocyte enzyme levels might serve as a surrogate marker 
of &-Nff in less accessible tissues (Kyrtopoulos et al, 1990). If the same relationship existed between 
liver and lymphocytes studies designed to assess the contribution of hereditary factors to the setting 
of &-MT levels in chronic liver disease, by measuring lymphocyte enzyme levels in a large cohort of 
patients and their families would have been made feasible. Such a correlation, however, was not 
found between diseased liver and lymphocytes in the present study. It was not possible to determine 
whether such a relationship existed between normal liver and lymphocytes due to the small number 
of normal liver biopsies available. Nevertheless, the finding of no correlation between liver and 
lymphocytes indicates that the differences in 06-MT levels seen between cirrhotic and non-cirrhotic 
liver are indeed disease- and target tissue-specific. 
The finding of low levels of 06-MT in cirrhotic tissue raises the question as to whether, at the cellular 
level, this deficiency is confined to hepatocytes, as opposed to non-parenchymal cells, and whether 
hepatocyte expression is heterogeneous. These are important questions as the susceptibility of 
cirrhotic tissue to carcinogenic damage may be expected to depend on the number of hepatocytes 
with low levels of 06-MT rather than the overall tissue levels. These points could be answered by 
either using either in situ hybridisation to localise 06-MT RNA or determining the intrahepatic 
distribution of the enzyme using immunohistochemistry. 
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3.5 Summary 
Micro-assay For Measuring Liver 06-MT 
* Using a combination of a DNA repair substrate of high 
specific radioactivity and optimising procedures for liver 
sample collection, storage, and enzyme extraction and 
assay, reproducible levels of 06-MT activity were able to be 
determined in small 5-15mg biopsy specimens. 
e Inter-assay variation was 11 
DNA Repair By 06-MT 
In Cirrhotic Tissue 
o 06ý-MT levels (mearuSEM): 
normal liver (n=6) 989±1 11 fmol/pg DNA 
non-cirrhotic diseased liver (n=19) 870±68 fmol/pg DNA 
cirrhotic (n=23) 540±57 fmol/pg DNA 
* 06-MT levels were significantly lower in cirrhotic liver 
than non-cirrhotic diseased liver (P=0.0006) or normal liver 
(P=0.01) 
* no correlation between liver and lymphocyte levels in 
patients with non-cirrhotic or cirrhotic liver disease, 
implying that deficient repair in cirrhosis is disease- and 
tissue-specific. 
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Chapter 4 
Production And Characterisation Of Polyclonal Antibodies To 
06. methylguanine-DNA methyltransferase 
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4.1 Introduction 
Tissue levels of native 01-MT can be reliably measured by direct enzyme assay, as described in 
Chapter 3, and can be taken as an indication of a the potential ability of a tissue to repair 
promutagenic DNA damage by environmental alkylating agents. However this provides a 
measurement of the tissue as a whole and takes no account of cellular heterogeneity in 06 -Mr 
expression. Heterogeneity may occur between different cell types within the same tissue. In the 
rodent lung Clara cells have a lower activity than alveolar cells (Belinsky et al, 1988). Similar 
heterogeneity is described in human kidney (Wani et al, 1992) and in the white blood cells where T 
lymphocytes have the greatest activity (Waldstein et al, 1982). 
These considerations are particularly relevant to liver tissue which comprises a heterogeneous 
population of cells; parenchymal cells (or hepatocytes) and sinusoidal cells (Kupffer cells, 
perisinusoidal cells, endothelial cells) and other non-parenchymal cells (such as portal fibroblasts). 
The parenchymal to non-parenchymal cell ratio varies between'normal and cirrhotic liver, the latter 
having a higher non-parenchymal component. In rat liver, parenchymal cells contain 4- to 5-fold 
higher levels of 06-MT than non-parenchymal cells (Swenberg et al, 1982). This observation has not 
yet been extrapolated to human liver. Nevertheless, it raises the possibility that the low levels of 06- 
MT observed in cirrhotic liver may simply reflect the expansion of the non-parenchymal cell 
population when compared with normal liver. It is also important to know whether the deficiency 
observed in cirrhotic tissue occurs in all hepatocytes as it may be that the number of cells deficient in 
the enzyme is more important than the overall tissue levels in relation to increasing susceptibility to 
carcinogens and thus the risk of tumour development. 
The full-length human 0'-MT cDNA was recently cloned in an &-MT deficient strain of E. coli using 
a system where bacteria containing the gene of interest were selected by their ability to grow in the 
presence of alkylating agents (Tano et al, 1990; Rydberg et al, 1990; Hayakawa et al, 1990). The 
protein sequence encoded by this cDNA contains 207 amino acids with a predicted M, of 21,700. The 
cysteine alkyl acceptor is probably at residue 145 within the sequence P"RV (residues 144-148) 
(Tano et al, 1990). Support for this suggestion comes from the fact that this sequence is homologous 
to that found in E-coli, yeast and rodent methyltransferases, and that amino acid substitutions of this 
cysteine results in complete loss of enzyme activity (Ling-ling et al, 1992). 
The cloning of human Cf-MT cDNA has made it feasible to produce antibodies to different regions 
of the protein from the predicted amino acid sequence. The aim of this study was to raise and 
characterise polyclonal antibodies to different peptide regions of 01-MT which could then be used to 
assess the tissue distribution of 0'-MT in order to assess differences between subpopulations of cells 
in normal and cirrhotic liver. 
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4.2 Materials and methods 
4.2.1 Reagents 
Casein blocldng buffer 
DAB (3,3'diaminobenzidine) 
0.5% casein (Hammarsten grade, BDH), 0.9% NaCl, lOmM 
Tris/HCI (pH7.6), 0.02% thimerosal (Sigma) 
0.1% DAB (Sigma), 137mM NaCl, 20mM Tris/HCI (pH7.6), 
lOmM imidazole (BDW 
Nickel-DAB reagent 137mM NaCl, 28mM nickel sulphate, 100mM sodium 
acetate, 10mM imidazole, 0.05% DAB (pH6.0) 
SDS-PAGE running buffer 0.025M Tris/HCI (pH8.3), 0.192M glycine, 
0.1% sodium dodecyl sulphate (SDS) 
Tris-buffered saline (TBS) 20mM Tris/HCl (pH7.6), 137mM NaCl 
Tris/glycine electroblotting buffer O. 2M Tris, 5OmM glycine 
SDS-PAGE sample buffer 4mls 10% SDS, 2mls glycerol (GIBCO BRQ, 1ml 2- 
mercaptoethanol (Sigma), 2.5ml 05M Tris/HCl (pH6.8) 
1.2ml 0.1% pyronin Y (Bio-Rad), 9.3mls 1120 
4.2.2 Peptide synthesis and conjugation 
Peptides MDKDCEMKRTTLDSPLGKLE (N-terminal or Pl), HEGHRLKPGLGGS (Internal site or 
P2), and KGAGATSGSPPAGRN (C-terminal or 173) were synthesised on an Applied Biosystems 
peptide synthesiser and their purity confirmed by high performance liquid chromatography, amino 
acid analysis and mass spectroscopy (Epitope Custom Peptides, Newcastle upon Tyne). A carboxyl 
terminal cysteine residue was added to P2 to facilitate hapten conjugation to keyhole limpet 
haernacyanin (KLH) carrier protein. 
P1 and P2 were conjugated to KLH (Pierce) through their cysteine residues using m- 
maleimidobenzoyl-N-hydroxysuccinimide ester according to the suppliers instructions (Pierce). P3 
was conjugated to glutaraldehyde-activated-KLH as follows: 20mg of KLH (Imjet, Pierce) was 
dissolved in 25ml H)D, and applied to a NAP-25 column desalting column (Pharmacia), equilibrated 
in OAM Na HCO3 then elutýd in 3.5ml of the latter. 5mg of P3 was dissolved in the eluate containing 
5mg of KLH. This mixture was made up to a total volume of 15ml with OAM NaHCO,, ), then mixed 
overnight at room temperature with 5pl of glutaraldehyde (EM grade, Sigma). P3-KLH conjugate 
was then, desalted /purified on a NAP-25 column, pre-equilibrated in PBS, according to the 
manufacturers instructions (Pharmacia) and eluted in a final volume of 3.5ml of PBS. The protein 
content of all eluates, containing purified conjugates, was measured by the Bradford method 
(Bradford, 1976) following sterile filtration through a 0.2pm membrane. 
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4.2.3 Immunisation 
Half-Lop rabbits were pre-bled to provide pre-immune sera, then immunised by multiple 
subcutaneous injections of 100pg MI. and P2) or 250pg (P3) of peptide emulsified with 1ml of 
Freund's complete adjuvent (Sigma)(Day 0). The immunisation protocol was in keeping with Home 
Office Guidlines under an approved license. Two rabbits were immunised with each peptide. This 
was followed by a second immunisation 14 days later with the same amount of immunising 
conjugate mixed with 1mI of Freund's incomplete adjuvent (Sigma). Antibody production was 
monitored by enzyme-linked immunosorbent assay (see below) on serum taken 7 days following a 
boost. Further immunisations with P2 and P3, were carried out on days 28,42,56 and 84. 
Immunisations with P1 were carried out on days 28,42,56,70, and 84. Rabbits were bled out on day 
105. Whole blood was allowed to dot at VC overnight, then serum was prepared by centrifugation at 
2000 rpm for 10 minutes, and stored in aliquots at -201C. 
4.2.4 Enzyme- linked immunosorbent assay (ELISA) 
Antigen (pure peptide) was bound to 96-well microtitre plates (Immulon 4, Dynatech) by overnight 
incubation at VC with 100pl of appropriate peptide (Pl, P2 or P3) at a concentration of ltig/ml In 
each well. Unbound peptide was aspirated from the wells which were then washed three times with 
200til of casein blocking buffer. Unreacted sites in the wells were then blocked by incubation with 
150pl of casein buffer for 1 hour at 37T. Serial dilutions of immune sera, in the range of 10-2 to 10-6. 
were then added in 100pl aliquots to the wells and incubated at 37*C for 60 minutes. The wells were 
emptied and washed as above, then incubated with 100pl of biotinylated goat anti-rabbit antibody 
(Amersham) diluted 1/1000 in casein blocking buffer for 1 hour at 37*C. Wells were aspirated and 
washed, then incubated with 100pl of streptavidin-biotinylated horse radish peroxidase (HRP) pre- 
formed complexes (Amersham) diluted 1/1000 in casein blocking buffer for 30 minutes at 37T. 
Following a final aspiration and wash, detection of HRP bound to the wells was accomplished by 
adding 100pl of TMB reagent (Bio-Rad) per well. The enzyme reaction was stopped by the addition 
of 50pl of 2M H2SO4 (BDH) to each well after 1 minute. The absorbance in each well was measured at 
405nm using a Titertek Multiscan MCC/340 ELISA plate reader. 
4.2.5 Antibody purification 
Anti-peptide antibodies were purified from crude rabbit sera by affinity chromatography on columns 
of immobilised peptide. 
Peptide conjugation to BSA 
P1 and P2 were coupled to BSA as follows: 2mg of peptide was mixed with 200PI of PBS and 
immediately with 2mg of Imjet maleimide-activated BSA (Pierce) dissolved in 200pl HP. The 
mixture was incubated for 2 hrs at room temperature and then made to lml with PBS. The 
conjugated peptide was purified by passage through a NAP-10 desalting column (Pharmacia), 
equilibrated in PBS according to the manufacturer's instructions. The protein content of the peptide 
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conjugate was measured as described by Bradford(1974). 
P3 was conjugated to glutaraldehyde activated BSA as follows. 20mg of BSA Umjet BSA, Pierce) was 
dissolved in 2.5ml H. 0, and purified by passage through a NAP-25 column, equilibrated and cluted 
with UM Na HCO3.5mg of P3 was dissolved in eluate containing 5mg of BSA. This mixture was 
made to a total volume of 1.5ml with O. 1M NaHCO3, then 5pl of glutaraldehyde (EM grade, Sigma) 
was added and the mixture left to react overnight at room temperature on a rotating mixer. 
Conjugated P3 was then purified on a NAP-25 column equilibrated In PBS. 
Coupling of peptide -BSA conjugates to Sepharose-B 
375mg of cyanogen bromide-activated Sepharose-B (Pharmacia) beads were washed and suspended 
in 5ml of 0.5M sodium phosphate buffer (pH7.5) to which was added 5mg of peptide-BSA conjugate. 
This mixture was left to react overnight at room temperature. The extent of conjugate bound to 
Sepharose was 57% for Pl, 94% for P2 and 42% for P3. The beads were then washed twice with 05M 
sodium phosphate (pH7.5) followed by 1M NaCl, 0.05M sodium phosphate (pH7.5). Unreacted sites 
on the cyanogen bromide activated Sepharose beads were quenched by overnight incubation at room 
temperature with 10 volumes of 100mM ethanolamine (pH 7.5 ) and gentle mixing. The beads were 
then gently washed twice in PBS and stored at VC after addition of thimerosal (Sigma) to a final 
concentration of 0.01%. 
Antibody purification by peptide affinity chromatography 
The antigen-bound cyanogen bromide-activated sepharose beads were transferred to a 1ml column. 
Crude antisera was affinity purified as described by Harlow and Lane (1988a) using the relevant 
peptide affinity column. 
Concentration of affinity-purified antibodies on columns of protein A- Sepharose 
Following antibody purification by peptide affinity chromatography, antibody fractions were 
concentrated using protein A-Sepharose (Harlow and Lane, 1988b). The eluted antibody fractions 
were assayed for total protein using the method of Bradford (1974). The antibody was localised to 
fractions 24 which were pooled and stored in 0.02% sodium azide at VC. The yield of purified IgG 
from immunised rabbits following affinity purification was of the order of 200-400pg/ml. Pre- 
immune sera was either purified by (a) protein A-Sepharose chromatography or (b) by 
immunopurification through a relevant peptide affinity column followed by protein A-Sepharose 
concentration as described above. 
4.2.6 Recombinant Oq-MT and cell lines 
A small amount of recombinant 06-MT, a generous gift of Dr P. Moody, Protein Structural Research 
Laboratories, Department of Chemistry, University of York, was available for use in the study and 
had an activity of 324 fmol/pI as supplied. Two cell lines were used: M9, derived from a colorectal 
carcinoma and known to overexpress 06-MT (Day et al, 1980) and VA13, derived from an SV40- 
transformed human embryonic lung cell line, which has barely detectable levels of 06-MT protein or 
mRNA (Day et al, 1980; Wang et al, 1992). 
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4.2.7 SDS-PAGE and gel electroblotting 
SDS-PAGE was performed using a discontinuous buffer system according to the method of Laemmli 
(1970) using 1.5mm thick 15% non-gradient polyacrylamide mini gels (10cm. x8 cm). 
Gel casting 
The constitution of the "resolving" and "stacking" gels are shown in Table 4.2.7. 
Table 4.2.7. Constitution of 15% polyacrylamide" resolving" gel and 4% polyacrylamide "stacking" gel. The 
volumes used were sufficient to pour 4 gels. 
Solution 15% resolving 
gel (I wer) 
4% stacking gel 
(uppeft_ 
40% acrylamide: bisacrylamide 37.5: 1 
(Amresco) 
15 MI. 2.01 ml. 
10% sodium dodecylsulphate (BDH) 400 pI 200 pl. 
O. SM Tris/HCI (pH 6.8)_ 5 ml, 
1.5M Tris /HCI (pH 8-8) 
__ 
10 MI. 
10% ammonium persulphate (Sigma) 2001d 100111 
N, N, N', N'-Tetramethylethylenediamine 
(TEMED)(Sigma) 
20 VI 81-d 
H20 14.38 ml U2.67 ml. 
Gels were cast in a mini-gel multiple casting device (Hoeffer Scientific Instruments) following the 
manufacturer's instructions. Once made, the gels were either used immediately or stored at 40C 
overnight wrapped in plastic film to prevent dehydration. 
Sample preparation 
Recombinant 0'-MT W-MT) was used in both in its native form and following methylation. rO6- 
MT was methylated by incubation with [YII-Me-DNA under conditions of the &-MT assay (see 
Chapter 3) for 90 minutes at 370C, then concentrated by methanol /chloroform precipitation (Wessel 
and Flugge, 1984) prior to SDS-PAGE. Sample concentration was done in this manner so that equal 
amounts of methylated and non-methylated enzyme could be analysed in parallel. Precipitated tests 
were resuspended in 20pl of sample buffer. Native r&-MT was mixed with BSA, 20opg per 100 fmol 
of enzyme, to prevent loss of protein during SDS-PAGE. 
HT29 and VA13 cell extracts were made and assayed as described for lymphocytes in Chapter 3. The 
HT29 cell extract had an activity of 56 fmol/lOpI or 1330 fmol/mg protein whilst the VA13 extract 
had undetectable levels of &-MT. 
Electrophoresis and blotting 
All samples were electrophoresed under reducing conditions as follows: prior to electrophoresis 
samples were heated with an equal amount of sample buffer at 95*C for 5 minutes, then cooled. Test 
samples (40pl maximal volume) and protein molecular weight markers (Pharmacia; low range) were 
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subjected to electrophoresis using a minigel electrophoretic system SE250 (Hoefer Scientific 
Instruments) at 20mA/gel for 60-90 minutes. Following electrophoresis proteins were transferred to 
nitrocellulose by electroblotting in Tris/glycine buffer for 20 hours at 170mA without cooling, 
according to the method of Towbin, using a TE22 Mighty Small Transphor wet, tank (Hoefer 
Scientific Instruments) (Towbin et al, 1979). 
4.2.8 Protein staining of gels and electroblots 
Polyacrylamide gels were subjected to general protein staining by microwaving for 2 minutes in 
0.125% Coomassie blue R-250 (Bio-Rad), 50% methanol, 10% acetic acid , and then destaining for 1 
hour in 50% methanol, 10% acetic acid followed by overnight destaining in 7% acetic acid, 5% 
methanol. Protein molecular weight markers electroblotted on to nitrocellulose were detected by 
staining with 0.1% amido black, 45% methanol, 10% acetic acid for 15 minutes followed by destaining 
in 70% methanol, 2% acetic acid for 40 minutes. The membranes were then rinsed in water and air 
dried. 
4.2.9 Immunoprobing of electroblots 
Electroblots of SDS-PAGE gels were blocked with 5% BSA dissolved in 20mM Tris/HCl (pH8.2), 
0.9% NaCI ("blocking buffer") for 2 hours and then cut into strips for probing with anti-peptide 
antibodies as follows. Strips were placed in the wells of a mini-incubation tray (BioRad) covered with 
400pl of primary antibody, diluted in 5% gelatin (Amersham), 20mM Tris/HCI (pH8.2), 0.1% BSA, 
0.9%NaCl, 1% goat serum, and incubated for 2 hours at room temperature. Membrane strips were 
then washed 3 times in 0.1% BSA, 20mM Tris/HCI (pH8.2), 0.9% NaCI and probed with biotinylated 
goat antirabbit -secondary antibody (Amersham) diluted 1/500 in 'blocking buffer" for 20 minutes. 
Strips were washed as above then incubated with pre-formed complexes of streptavidin-biotinylated 
horse radish peroxidase (Amershým) diluted 1/1000 in "blocking buffer" for 20 minutes. After 
further washing the strips were rinsed in H20. Peroxidase associated with the membrane was 
detected using nickel-DAB as the enzyme substrate as follows. 10mls of nickel-DAB was mixed with 
HP2 (added to a final concentration of 0.02%) then filtered and immediately applied to the 
membrane strips for 5 minutes. The reaction was stopped by washing in H20. 
4.2.10 Immunocytochemistry 
Preparation of cell lines. 
HT29 and VA13 cell lines were grown near to confluency on coverslips in Minimal Essential Medium 
Eagle (Sigma). Coverslips; were then removed and washed in PBS. Cells were fixed by soaking the 
coverslips in either 100% acetone, 100% methanol or 4% paraformaldehyde for 10 minutes, then 
washed in PBS and air dried. Coverslips were attached to slides using DPX mountant (BDH) and 
stored at -20*C prior to use for immunostaining. 
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Immunostaining 
Slides which had been stored at -20*C were allowed to warm to room temperature and then 
equilibrated in TBS. Protease digestion was achieved by a 10 minute incubation in 0.1% saponin. 
Non-specific binding was then blocked by incubating the slides with 3% normal swine serum (NSS) 
in TBS for 10 minutes. Coverslips were then covered with 100pl of primary antibody, diluted from 
1/10 to 1/100 in TBS, or in 0.1% saponin in those cases where protease digestion had been 
undertaken, overnight at VC. Immunostaining was then detected using an indirect 
immunoperoxidase technique. Briefly, cells were washed in two 5 minute changes of TBS and 
incubated in 100pl of peroxidase -conjugated swine anti-rabbit immunoglobulin (Dako) at a diluted 
to 1/20 in NSS for 30 minutes. Following two further 5 minute washes in TBS cells were incubated 
with PAP (complex of horseradish peroxidase and rabbit anti-horseradish peroxidase) (Dako) diluted 
1/50 in NSS for 30 minutes. Cells were again washed and immunolabelling was detected using 
filtered DAB containing 0.02% H20z The reaction was stopped by washing in water. Cells were 
counterstained with Mayers haernatoxylin followed by Scott's tap water (Sigma), to enhance the 
nuclear counterstain, and mounted under coverslips; using Glycergel (Dako). 
4.2.11 Immunohistochemistry 
5pm sections of normal human frozen liver, which had been embedded in OTC (Miles Inc, Elkhart, 
USA), and 3prn sections of paraffin-embedded normal liver tissue were attached to poly-L -lysinc 
treated slides. The paraffin-embedded tissue used had been fixed in either 10% buffered formalin, 
4% paraformaldehyde, or Bouin's solution. Paraffin-embedded sections were then dewaxed in xylene 
for 10 minutes and then rehydrated through graded alcohols (100% to 95% to 70%) to water. All 
sections were then equilibrated in TBS. Enclogenous peroxidase was blocked by incubation in 0.5% 
hydrogen peroxide in methanol for 10 minutes. Where indicated some sections were protease- 
digested by incubation with 0.1% trypsin in 0.1% Caq(pH7.8) for 10 minutes at 37*C. Non-specific 
antibody binding was blocked by pre-incubation of the sections with 3% normal swine serum (NSS). 
Anti-peptide antibodies against &LMT, that had been affinity -purified on columns of immobilised 
peptide, were used at dilutions between 1/10 to 1/100 in NSS. Incubations were performed using 
100pl per section overnight at VC in moist incubation trays. Immunostaining was then performed 
using the indirect immunoperoxidase method followed by 3,3'diaminobenzidine as the chromagen 
as described above. 
Sections which had been initially paraffin-embedded were then immersed in Lugols iodine for 3 
minutes followed by 1% hypochlorite to remove any mercury present from the tissue fixative, and 
then counterstained. with Mayers haernatoxylin followed by Scott's tap water. Tissue sections were 
then dehydrated through 75%, 90% and 100% ethanol, immersed in xylene and mounted under 
coverslips using DPX mountant. Frozen liver sections were counterstained with Mayers 
haernatoxylin followed by Scott's tap water and mounted under coverslips using Glycergel (Dako). 
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4.3 Results 
4.3.1 Selection of peptides 
Three peptides, peptides P1, P2 and P3, were predicted from the cDNA derived amino acid sequence 
(Tano et al, 1990) to be immunogenic based on hydrophilicity analysis (Hopp and Woods, 1981; 
Hopp, 1986; Kyte and Doolittle, 1982). These peptides contained amino acids 1-20,171-184 and 193- 
207 of the predicted 207 amino acid sequence, and arise from the amino- and carboxy- termini 
regions and an internal site downstream from the highly conserved methyl acceptor site. The methyl 
acceptor site was not predicted to be antigenic (Figure 43.1). 
4.3.2 Antibody production 
All of the peptides usedproduced a good immune response as evidenced by the reaction of the rabbit 
antisera in ELISA against peptide-coated plates. Figures 4.3.2a, b and c show the rise in antibody titre 
in the 6 rabbits during the immunisation protocol. Antisera from rabbits A, D and F raised against 
peptides P1, P2 and P3 respectively gave the highest titres in ELISA and were used in 
immunoblotting experiments and immunocytochemistry. 
4.3.3 Antibody specificity 
The specificity of the antisera for 
66-MT 
was evaluated by testing their ability to detect recombinant 
06-Nff following SDS-PAGE and electroblotting. Human recombinant 06-MT as supplied was about 
80% pure and was detected as a M,. 24,000 band when resolved by SDS-PAGE (Figure 4.3.3a). 
Although 06-MT has a predicted Mr of 21,700 it exhibits slightly higher mobility by SDS-PAGE, 
giving a M, of about 24,000; this is thought to be due to anomalous electrophoretic mobility of the 
enzyme (Koike et al, 1990). In preliminary studies variable amounts of rO6-MT were detected on 
immunoblots following SDS-PAGE despite equivalent protein loading. This suggested that either 
the protein was not being carried from the "stacking" to the "resolving gel" during SDS-PAGE or the 
protein was not being transferred to membrane during electroblotting, and was probably a reflection 
of the small amount of protein used (less than 10ng). The problem was overcome by the the addition 
of a carrier protein, in the form of BSA, to rO6-MT before SDS-PAGE resulting in increased transfer of 
the enzyme and thus a more intense 4 24,000 band detected by immunoblotting as shown in Figure 
4.3.3b. The M,, 57,000 band seen, when rO6-MT was run with BSA, on the immunoblot in Figure 
4.3.3b represents non-specific protein binding of the anti-N-terminal (anti-PI) antibody to a 
component of the BSA, this band is also seen in Figure 4.3.3d; lane 1. 
All three affinity-purified anti-peptide antisera reacted with recombinant 06-W producing a band of 
M, 24,000 on immunoblots (Figure 4.3.3c). Methylation of the enzyme did not appear to introduce a 
gross conformational change involving the three different epitopes recognised by the antibodies as 
all three antibodies reacted with methylated recombinant 06-MT on immunoblots (Figure 4.3.3d). 
Antibody specificity was also tested by investigation of their ability to react with &-MT in extracts of 
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180 190 
GATSGSPPAGRN 
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Figure 4.3.1: Predicted amino acid sequence of 06 -MT, from cDNAf indicating the three peptides (underlined) used to raise polyclonal antibodies. 
Pl: amino acids 1-20 (N-terminus), P2: amino acids 171-184, and PI amino 
acids 193-207 (C-terminus). 7he cysteine methyl accepting site at the enzymes 
active centre is circled. 
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Rabbit A 
1.5 
1.0 
Absorbance 
(405 nm) 
0.5 
0.0 
Preimmune 
Day2l 
Day 35 
Day 49 
Day 63 
Day 77 
Day9l 
Day 105 
Rabbit B 
1.5 
1.0 
Absorbance 
(405 nm) 
0.5 
0.0 
- Preimmune 
- Day2l 
- Day 35 
- Day 49 
- Day 63 
- Day 77 
- Day 91 
- Day 105 
Figure 4.3.2a: Immunoreactivity determined by ELISA of rabbit antisera. 
Rabbits A and B were immunised with Pl- KLH conjugate, and tested at the 
dilutions shown on days 0 through to 105 of the immunisation protocol. 
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Dilution 
10 -1 , ö2 10-3 10-4 10.6 10,6 
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Rabbit C 
1.5 
1.0 
Absorbance 
(450nm) 
0.5 
0.0 
1.5 
1.0 
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(450nm) 
0.5 
0.0 
Preimmune 
Day 21 
Day 35 
Day 49 
Day 63 
Day 91 
Day 105 
Preimmune 
Day 21 
Day 35 
Day 49 
Day 63 
Day 91 
Day 105 
Figure 4.3.2b: Immunoreactivity determined by ELISA of rabbit antisera. 
Rabbits C and D were immunised with P2- KLH conjugate, and tested at the 
dilutions shown on days 0 through to 105 of the immunisation protocol. 
Rabbit D 
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Rabbit E 
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(450nm) 
0.5 
0.0 
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- Day 35 
- Day 49 
- Day 63 
- Day 91 
- Day 105 
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- Day 21 
- Day 35 
- Day 49 
- Day 63 
- Day 91 
- Day 105 
Figure 4.3.2c: Immunoreactivity determined by ELISA of rabbit antisera. 
Rabbits E and F were immunised with P3- KLH conjugate, and tested at the 
dilutions shown on days 0 through to 105 of the immunisation protocol. 
Rabbit F 
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Mr 2 
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I igure 4.3.3a: SDS-PAGE of human recombinant (7'-M I ('-(7'-M I ). Coomil,,, sle Wile 
stained 15% polyacrylamide gel. Lane 1: 70ng of r(YWT; hine 2: 35ng of r(Y'-M'I'. 
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I igure 4.3.3b: Effect of adding carrier BSA to rCY'-M'I prior Io SOS-PAGE (A) 2.2ilg of 
rOý-MT, (B) 2.2ng of r06-MT + 25lig of' BSA. lleptide affinity-purified (1110-111 (N- 
terminal) antibodýy was used to probe electroblot strips tit a concentration of 3pglml. 
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mr anti-Pl anti-P2 anti-P3 
(X103) 
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Vigure 4.3.3c: Native (n on -niethyla tedlac five) r06-M'I'detected on electroblot strips b' i/ the3 
different anti-peptide antibodies. Anti-P] (directed against the N-terminus of Ihe enzyme), 
anti-P2 (directed against an internal site) and anti-P3 (directed again-st the C-terminus) 
antibodies. 2.2ng of rob-M'j, in each lane was subj'ected to SOS-IIAGL anti elecIroblot strips 
uyere probed with anti-P] (3ligInd), anti-P2 ( 7pglml), and anti-P3 OligInd) antibodWs (till 
affini(y-purified on peptide columns). 
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Mr anti-Pl anti-P2 anti-P3 
(Xie) 
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43 - 
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Figure 4.3.3d: Methylated WO-MT detected oil electroblot strips by the 3 different anti- 
peptide antibodies, Anti-PI (directed against the N-terminus of' the enzyme), anli-1127 
(directed aga inst ail internal site) and anti-P3 (directed against the C-terininus) antibodies. 
8.8ng of rOO-MT in each lane subjected to SDS-PAGE and electroblot strips were probed 
with : anti-PI (3pglinl), anti-P2 (7jiglinl) anti-P3 (3jigInd) antibodies (till affinity-purified 
on peptide columns). 
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HT29 cells which contain high levels of the enzyme, and VA13 cells which have no detectable 
enzyme activity. Ant-P1 (N-terminus) and anti-P3 (C-terminus) anti-peptide antibodies detected 06- 
MT in HT29 cell extracts as evidenced by a band of M, 24,000. This band was not present in VA13 
exfracts (Figure 4.3.3e and f), demonstating that the antisera are able to detect &-MT in crude cell 
extracts. Clearly these antisera cross-react with other proteins in the crude cell extracts as indicated 
in Figure 4.3.3e where a band of 18,000 is also detected by the N-terminal antibody in both the IM9 
and VA 13 cell extracts. However, no Mr 24,000 band, corresponding to 0'-MT was seen with 
preimmune sera which had been purified by protein A-Sepharose chromatography or by 
immunopurification through a relevant peptide affinity column. Insufficient rO6-MT was available 
for further pTeabsorption experiments using excess enzyme to block antibody reaction in order to 
further test the specificity of the antisera. Nevertheless preabsorbing anti-P3 (directed against the C- 
terminal) with an equivalent amount of recombinant enzyme convincingly reduced the intensity of 
the Mr 24,000 band in the HT29 extract (Figure 4.3.3f) indicating that this band represents &-MT. 
Anti-P2, directed against an internal domain of the enzyme, did not recognisc 06-MT in the HT29 or 
VA13 cell extract. 
4.3.4 lmmunocytochemistry 
The ability of the antibodies to specifically immunolocalise 0'-MT in intact cells was assessed by 
immunocytochemistry of HT29 and VA13 cell lines. Cell staining was most intense when the cells 
had been fixed in 100% acetone as opposed to methanol or paraformaldehyde. Strong cytoplasmic 
immunoreactivity with perinuclear accentuation was detected in the HT29 cell line but with no 
associated nuclear staining using the anti-P3 (C-terminal) affinity purified antibody (Figure 4.3.4a). In 
contrast minimal staining was seen in the VA13 cell line (Figure 4.3.4b). Some cytoplasmic staining 
was seen in HT29 cells with preimmune serum, but only following concentration of the serum on a 
protein-A Sepharose column. Preimmune sera which had been 'sham' affinity-purified on a column 
of immobilised peptide did not stain HT29 cells (Figure 4.3.4c). No staining was seen in either cell 
line with anti-P1 or anti-P2 affinity purified antibodies. 
4.3.5 Immunohistochemistry 
None of the three antibodies developed were able to detect 06-MT in frozen liver tissue or paraffin- 
embedded liver tissue sections despite the use of different tissue fixatives and protease digestion of 
the tissue sections. 
4.4 Discussion 
Antibodies to 06-MT were first developed in 1990 when monoclonal antibodies were raised against 
partially-purified human 06-MT (Brent et al, 1990). Subsequent cloning of the full length 01-W 
coding DNA has now allowed other groups to develop anti-peptide antibodies to regions of the 
predicted protein sequence ( Pegg et al, 1991a; Ostrowski et al, 1991b). These antibodies have been 
characterised in Western blotting but have not been used to immunolocalise the protein in tissue 
71 
Mr rOP-MT HT29 VA13 
(Xlcp) 
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Vigure 4.3.3e: SDS-11AGElimmunoblotting of crude extracts prepared from an enzyme 
proficient and enzYme deficient cell line. 80lig of extract protein from 11'129 (()"-M'I' 
proficient) and VA13 (06-MT deficient) cells, and rOO-MT. Electroblot strijy, ý were probed 
with anti-PI (N-terminal directed) antibodýy used tit a concentration of 31iglnil. Lanes 1-3 
contain 100finol, 112finol, and Oftnol of 06-MT respectiveýy predetermined by direct 
enzyme assay . 
71 
Mr HT29 VA13 
(X103) 
67 
43 
30 
20-1 
14.4 
B 
67 
43 
30 
20.1 
14.4 
1 
JI 
1 
-vKM, 24,000 
-'a Mr 24,000 
Figure 4.3.3f: SDS-PAGElimmunoblotting of crude extracts prepared front an enzyme 
proficient and enzyme deficient cell line. 80jig of extract protein from 11'129 (C)"-M'I' 
proficient) and VA13 (06-MT deficient) cells. Electroblot strips were probed 'with anti-113 
(C-terminal directed) antibody tit a concentration of 3liglinl. (A) Lane 1: HT29 0 12finol of 
C)6-M, l 'determined by direct enzyme assay); Lane 2: VA13 (no 01-M'I'detected by threct 
enzyme assay). (B) HT29 extract (112finol) run in both lanes and probed wifli anti-113 
antibody Qpglinl; lane 1); and anti-P3 (3jiglinl) antibody preabsorbed with an equal niolar 
amount of r06-MTprotein (lane 2). 
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Figure 4.3.4a: HT29 cell line, containing 1330finollmg protein of 06-M'I'as determined by 
enzyme assay. (A) Stained with haematoxylin and eosin to show cell morphology. (B) Strong 
cytoplasmic immunoreactivity in HT29 cells with immunopurified anti-P3 antibody 
(directed against the C-terminus of 06-MT). Anti-P3 used at a concentration of 30pglml. 
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Figure 4.3.4b: VA13 cell line, containing undetectable levels of 06, -MT as determined by 
enzyme assay. (A) Haematoxylin and eosin staining of the cell line to show cell morphology. 
(B) Minimal cytoplasmic immunoreactivity with anti-P3 antisera (directed against the C- 
terminus of 06-MT). Anti-P3 used at a concentration of 30pglml. 
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Figure 4.3.4c: Specificity of cell staining with anti-P3 antibody. (A) C! ytoplasmic staining in 
cells from the HT29 cell line with anti-P3 antisera (directed against the C-terminus of ()6- 
MT). (B) Absence of immunoreactivity in the same cells with preimmune sera. 
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sections. 
In the present study all three anti-peptide antibodies recognised native (non-methylated /active) 
recombinant &-MT. Methylation of recombinant protein, as a result of enzyme action on methylated 
radiolabelled calf thymus DNA, did not substantially affect the tertiary structure of the protein as all 
three antibodies were also able to detect the methylated form of the protein. However, the reaction 
against the three sites on the methylated enzyme was less intense suggesting that either loss of 
enzyme had occured during sample concentration by methanol /chloroform precipitation or some 
minor change in conformation of the enzyme had occured following methylation that affected the 
affinity of the antibody for the epitope. Conforniational change on methylation occurs with the 
bacterial ada gene product (Lindahl et al, 1988), and it has been suggested that a similar change 
occurs in the human enzyme based on the observation that certain anti-peptide antibodies can 
precipitate the methylated (inactive) but not native (non-methylated /active) enzyme (Ostrowski et 
al, 1991b). 
That two of the antibodies, those recognising the N and C-terminal domains but not the antibody 
recognising the internal domain, were able to detect 06-MT in crude cell extracts suggests a 
structural difference between native enzyme and recombinant OkMT. The specificity of these 
antibodies was confirmed by the absence of detectable enzyme atM, 24,000 in extracts from the VA13 
cell probed with the anti-peptide antibodies, and in the HT29 extracts when reacted with pre- 
immune sera. However the antibodies also cross reacted with other protein bands on immunoblots, 
as has been reported by other groups. This limits their usefulness for analysis of the enzyme in crude 
cell extracts. The inability of anti-P2 antisera to recognise 06-MT in the HT29 cell extract was 
unexpected as a polyclonal antibody raised to an identical peptide was shown to detect the enzyme 
in a crude cell extract from the CEM cell line (Ostrowski et al, 1991b). 
The intense cytoplasmic/perinuclear staining of HT29 cells by antibody recognising the C-terminus 
of d-W is of interest as in the course of this work cytoplasmic staining of human hepatocytes was 
observed by Lee et al (1992) using a polyclonal antibody raised against recombinant protein. As the 
antibody binds non-specifically to other proteins in crude HT29 cell extracts on immunoblots, it is 
not possible to conclude that such staining represents evidence of 06-MT within the endoplasmic 
reticulurn of these cells. Nevertheless, the specificity of the staining for 06-MT was supported by the 
negligible immunoreactivity seen in the enzyme deficient VA13 cells. It should be noted that 
although VA13 cell enzyme activity is undetectable using the enzyme assay reported In Chapter 3 the 
cells do contain a small amount of enzyme, about 400 molecules /cell (Wu et al, 1987) and a small 
amount of 06-MT RNA, detected by polymerase chain reaction, which would account for some of 
the weak staining in the VA13 cells. However, the presence of cytoplasmic staining with 
concentrated pre-immune IgG suggests that some of this labelling is non-specific and this is 
supported by the lack of staining with 'sham' peptide affinity-purified pre-immune sera which 
removed non-specific binding immunoglobulin. 
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Although the expected location of 06-MT immunoreactivity is nuclear, as 06-MT repairs DNA, the 
presence of cytoplasmic staining does not exclude specific 06-MT detection as the Intracellular 
distribution of the enzyme in human tissues is still unknown. Subcollular distribution of 06-MT in rat 
liver has been addressed using enzyme assays of subcellular fractions. The cytosol has variously been 
reported to contain 35% Gun et al, 1975), 59% (Pegg et al, 1983) and 72% (Hora et al, 1983) of total 
cellular activity. 06-MT has also been isolated from rat liver mitochondria (Myers et al, 1988). More 
recently Ayi et al (1992) have reported immunolocalisation of 06-MT in human cell lines using a 
polyclonal antibody raised against recombinant protein. Although staining was predominantly 
nuclear some cell lines showed cytoplasmic immunoreactivity. Whether or not any &-MT is ever 
cytoplasmic in location in vivo remains unclear. The reported distribution of 06_MT may just 
represent leakage of nuclear enzyme into the cytoplasm during tissue preparation and fractionation. 
It is possible, however, that there are different forms of the enzyme in different cellular 
compartments and it has been suggested that the cytoplasmic enzyme may be a mutant form of the 
nuclear enzyme that lacks a nuclear localisation sequence and is, thus, non-functional because of its 
inability to access nuclear DNA (Ayi et al, 1992). This is an important consideration as the sensitivity 
of such cells to alkylating agents might not be reflected by quantification of levels by direct enzyme 
assay or other approaches that involve measurement of total cellular 06-MT activity. 
The inability to detect 06-MT in liver sections immunohistochemically reflects the difficulty in 
producing antibodies that detect epitopes under a variety of conditions, such as &-MT bound to a 
solid phase in the ELISA approach, denatured in SDS-PAGE and altered by tissue fixatives in 
paraffin-embedded tissue sections. Although in the present study epitopes on &-MT might have 
been masked during tissue fixation such an explanation does not account for the inability to detect 
the enzyme in frozen liver tissue. It is, however, not uncommon for anti-peptidc antibodies to detect 
denatured protein but not native antigen in vivo. Using anti-peptide antibodies of similar specificity 
other groups have also failed to detect the enzyme in tissue sections (Pegg et al, 1991a; Ostrowski et 
al, 1991b). While the present study was in progress, Lee et al (1992) managed to detect 01-MT in 
paraffin-embedded sections of normal human liver using antibodies raised against recombinant 
enzyme; they did not study any form of liver disease. The enzyme was localised to the nucleus in 
most cells but in some cells there was coexistant cytoplasmic staining, as has also been reported 
occur in human cell lines (Ayi et al, 1992). Although staining was confined to the hepatocytes, with 
little immunoreactivity in non-parenchymal cells, not all hepatocytes expressed 06-MT. These 
findings indicate the importance of comparing levels of 0'-MT from whole tissues extracts with the 
cellular distribution of the enzyme. Normal liver, a tissue with one of the highest levels of 0'-W 
activity, would be expected to be relatively resistant to the effects of alkylating agent damage but the 
presence of hepatocytes which do not contain immunoreactive enzyme indicates that there is a 
subgroup of cells which are likely to be more susceptible to DNA base damage than is suggested by 
the enzyme assay findings. 
Two of the antibodies produced in this study detected the native (non-methylated /active) and 
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methylated (inactive) 06-MT in immunoblots of enzyme -containing cell extracts. These antibodies, 
directed against two distinct parts of the enzyme, namely the N- and C-termini, should therefore be 
useful in future studies characterising 06-MT in cirrhotic liver. These antibodies provide a means of 
establishing a quantitative method for measuring 06-MT by SDS-PAGE/immunoblotting. This could 
potentially enable the total amount of enzyme in vivo (native and endogenously methylated) to be 
measured immunochernically in extracts. An estimate of the amount of methylated (inactive) enzyme 
present in the extract could then be obtained by subtracting the amount of native (non- 
methylated /active) enzyme, calculated from the direct enzyme assay, from this value. The level of 
methylated enzyme in an extract would be an indirect measure of the tissue's exposure to 
endogenous alkylating agents, that is a "fingerprint" of the extent of recent DNA damage; this is 
considered further in Chapter 5. 
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4.5 Summary 
Production and characterisation of anti-peptide antibodies to 
06-MT 
- Polyclonal anti-peptide antibodies raised to regions of the enzyme predicted 
to be antigenic: 
- N-terminal (amino acids 1-20; anti-Pl) 
- Internal site (amino acids 171-183; anti -P2) 
- C-terminal (amino acids 193-207; anti-P3) 
- SDS-PAGE and Immunoblotting: 
- AJI antibodies specifically detected native (non-methylated) 
and methylated (inactive) human recombinant 06. MT 
- N-terminal and C-terminal directed antibodies detected 06. 
MT in crude cell extracts of enzyme-rich HT29 cells but not in 
extracts of enzyme-deficient VA-1 3 cells confirming antibody 
specificity. 
- Immunocytochemistry: 
- Cytoplasmic staining of HT29 cells with C-terminal antibody 
- Immunohistochemistry 
- None of the antibodies detected 06-MT in frozen or paraffin- 
embedded liver tissue sections and therefore cannot 
comment on the heterogeneity of enzyme expression in the 
liver. 
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Chapter 5 
Characterisation Of 06-methylguanine-DNA methyltra nsfe rase In 
Cirrhosis 
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5.1 Introduction 
Elucidation of the physicochen-dcal properties of 06-methylguanine-DNA m&yltransferase O-MT) 
have been hindered by its relatively low tissue abundance and the notorious. instability it displays 
when subjected to protein fractionation. The enzyme has therefore only recently been fully purified 
and has not as yet been subjected to physicochemical analysis (Brent et al, 1990). Nevertheless, the 
06-Nff gene has been cloned and the predicted amino acid sequence determined which is comparable 
with sequences obtained from partial protein purification (Tano et al, 1990; von-Wronski et al, 1991). 
Physicochemical studies of the recombinant enzyme have been undertaken (Koike et al, 1990) and it 
is likely that knowledge of the tertiary structure of Oý-MT will come from further analysis of the 
recombinant enzyme. I 
Although levels of the enzyme vary widely between human tissues, it is not known whether these 
differences are reflected in structural differences in the enzyme, the presence of more than one form of 
the enzyme, as is the case in procaryotes, or different rates of enzyme turnover in different tissues. 
Larger molecular weight forms of the enzyme have been reported in human lymphoid tissue (Major et 
al, 1990) and rat liver (Myers et al, 1988) but the significance of these larger forms in terms of the 
setting of tissue enzyme levels is unclear. Native 06-Mr acts by removing methyl groups from the 01 
position of guanine in DNA which it transfers to its own specific cysteine residue and thus in the 
process becomes both methylated and inactivated. The fate of the methylated enzyme, which is not 
regenerated, is not known, although a recent study has suggested that it is rapidly degraded (Pegg, 
1991b). 
Although human liver has one of the highest tissue levels of Ok-MT little is known about the 
structure of the enzyme in normal liver. It is not dear whether structural changes occur in disease to 
account for the findings of low levels of native (non-methylated /active) enzyme in human cirrhotic 
tissue compared to non-cirrhotic diseased liver and normal liver (see Chapter 3). Thus, it is possible 
that cirrhotic and non-cirrhotic liver contain different enzyme forms which have different activities. 
C-terminal degradation of Oý-MT has been reported in normal liver (Pegg et al, 1991 a) raising the 
possibility that degradation may be marked in cirrhotic liver leading to the observed lower levels of 
active enzyme. The availability of extracts from cirrhotic, non-cirrhotic and normal liver has 
enabled some of these questions to be addressed by SDS-PAGE analysis of the enzyme in these 
extracts using the techniques of fluorography and immunoblotting with anti-peptide antibodies 
recognising 06-Nff (whose development was outlined in Chapter 4). These experimental approaches 
allow the detection of both native O%ff and total (native and endogenously mcthylated /inactive) 
enzyme in tissue extracts (Figure 5.1). SDS-PAGE/fluorography of extracts, containing [11_MeIO6. Nff 
(native enzyme methylated and radiolabelled with tritium), allows native enzyme to be visualised 
as a band on fluorograrns. In contrast SDS-PAGE followed by immunoblotting allows the detection of 
both native and methylated 06Wr. 
The aim of this part of the study was four -fold: (i) to confirm the direct enzyme assay findings of 
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6 Figure 5.1: Experimental approaches used to detect 0 -MT in tissue extracts. 
(A) SDS-PAGElelectroblotting followed by fluorography detecting native enzyme (methylated 
and radiolabelled in vitro). (b) SDS-PAGElelectroblotting followed by immunochemical 
detection using antibodies which detect both methylated and non-methylated enzyme. 
[3 H-Me] 06_MT 
in vt 
methylation 
or 
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low levels of Oý-MT in cirrhosis using SDS-PAGE/fluorography and quantitative densitometry, (ii) to 
establish the presence or absence of different molecular weight forms of the enzyme; (iii) to look for 
possibility of C-terminal protease degradation of the enzyme, Ov) to compare total enzyme levels 
(native/non-methylated and endogenously methylated /inactive enzyme) with levels of native 
enzyme measured by the enzyme assay. 
5.2 Methods 
5.2.1 Preparation of samples 
Liver tissue was available from 36 of. the 48 patients studied in Chapter 3 (cirrhotic, n= 15, non- 
cirrhotic diseased liver, n=17; normal liver, n--4). Lymphocytes from 7 of these patients were also 
available for study. Liver and lymphocyte extracts were prepared as described previously (Chapter 
3). Extracts, where indicated, were incubated with excess tritiated methylated calf thymus DNA 
(substrate) at 37*C for 90 minutes to methylate and radiolabel all the enzyme in the extract. A 
repeat direct enzyme assay was carried out on all the extracts (as described in Chapter 3) prior to 
SDS-IIAGE. Extracts were mixed with sample buffer containing Pyronin Y and then subjected to SDS- 
PAGE (see Chapter 4). 
5.2.2 Immunoblotting 
Liver and lymphocyte extracts were separated by SDS-PAGE in 1.5mm non-gradient 
15%polyacrylamide gels under reducing conditions, blotted on to 0.21im nitrocellulose membrane that 
was subsequently probed with N- and C-terminal directed anti-peptide antibodies as described in 
Chapter 4. 
5.2.3 Fluorography 
Human recombinant 06-MT and cell and tissue extracts produced to contain ftf-Mel enzyme were 
subjected to SDS-PAGE using 15% polyacrylamide gels as described in Chapter 4. [14C] labelled low 
molecular weight protein markers (GIBCO BRQ were run on all gels. Following electrophoresis, gels 
were electroblotted onto polyvinylidene difluoride (PVDF)(BioRad) rather than nitrocellulose 
membrane. PVDFwas used according to the manufacturers instructions and following electroblotting 
was washed In water, allowed to dry and then sprayed with'En3hance' spray (New England 
Nuclear-Dupont) and Tedried. X-ray film (Fuji RX) was preflashed from a distance of 45cm using a 
'Sensitize'preflashing gun (Amersham) in order to increase the sensitivity of the film to low light 
emissions (Roberts, 1985). The PDVF membrane was then exposed to the x-ray film at -8011C for 4 
weeks. The linearity of the response of the film to low intensity emissions following preflashing was 
established in preliminary work (personal communicatiort, Dr GN Major). 
5.2.4 Densitometry 
Densitometric analysis of the fluorograms and immunoblots were performed on a Biolmage laser 
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densitometer (Millipore, USA) linked to a Sun computer. The fluorograms were analysed using 
"whole band analysis" and the immunoblot strips by I-D analysis". Data are expressed as an 
integrated optical density (IOD) which is a measure of the overall band intensity. The molecular 
weight of the bands on fluorograms, and immunoblots were determined by measuring their Rf value 
which was compared with those of the protein standards run on each gel. 
Statistics were performed as described in Chapter 3. 
5.3 Results 
5.3.1 Levels of OWT In cirrhosis 
SDS-PAGE/fluorography/densitometry provides not only another method for measuring the level of 
native OkMT in tissue extracts but it has the advantage of also allowing physicochemical 
characterisation of the enzyme. A band of Mr 24,000, representing M-Mel OkMT was seen on all 
fluorograms. This indirect method of measuring the native enzyme was calibrated by showing that a 
linear relationship existed between integrated optical density, a measure of the intensity of the M, 
24M band, and the amount of OkMT in the HT29 extract (Figure 5.3.1 a). The amount of OINff 
detected by SDS-PAGE/fluorography/densitometry varied by 2-4% on different days, comparable 
with the direct enzyme inter-assay variation of 2-4% previously reported by Major et al (1990). 
Enzyme levels in the liver extracts, as determined by the direct enzyme assay (see Chapter 3), 
correlated with the Mr 24,000 band intensity UOD) associated with the fluorograms ( r=0.78, 
p=0.0001). Native Oý-MT levels differed significantly between cirrhotic, non-cirrhotic and normal 
liver extracts (ANOVA; F=10.89, p=0.0002) when measured by SDS-PAGE/fluorography/ 
densitometry. 06-? vIT was significantly lower in cirrhotic tissue extracts compared with non-cirrhotic 
(p=0.0002) and normal liver extracts (p=0.0015) (Figure 5-3.1b). These findings are, therefore, 
comparable with 06-Mr levels detected using the direct enzyme assay as described in Chapter 3. 
5.3.2 Multiple molecular weight forms of Oq-MT 
In addition to the expected band of M, 24,000, representing Oý-MT, lower molecular weight forms 
were also seen following SDS-PAGE/fluorography. In the liver extracts up to three additional bands 
were consistently visualised at M, 23200, Mr 21,8W and M, 20,900. All four molecular weight forms 
were seen in cirrhotic, non-cirrhotic and normal liver (Figure 5.3.2a). Smaller bands of M, 23,200; 
22,500; 21,800; 19,500; 17,900; 16,800; 15,400; 13,400 and 9,400 were also detected in lymphocyte 
extracts and in recombinant enzyme; and compared with liver, a larger number of bands with 
different molecular weights were apparent (Figure 5.3-2b). The finding of smaller enzyme forms may 
be due to either endogenaus protease action or different distinct forms of the enzyme. Repeat direct 
enzyme assay of the lymphocyte extracts prior to SDS-PAGE showed that no loss of activity had 
occurred during storage, indicating that appearance of the lower molecular weight enzyme forms in 
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Figure 5.3.1a: Calibration of SDS-PAC; Flfliioro, ýt-tilihylili, tisi'toilli, ti-. II lor 
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Figure 53.1b: Levels of d-MT determined by SDS-PAGElfluorographyldensitometty 
in cirrhotic, non-cirrhotic diseased liver and normal liver. Mean levels are shown by 
horizontal lines and their values : tSEM are indicated below the graph. 
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Figure 5.3.2a: Fluorqgrams of SDS-PAGElelectroblots of liver extracts. Two representative 
samples from normal, non-cirrhotic and cirrhotic liver are shouln. 
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this enzyme source was not associated with loss of enzyme activity. No molecular weight forms larger 
than Mr 24,000 were identified by SDS-PAGE/fluorography in either liver or lymphocyte extracts, but 
a faint band of Mr 27,000 was seen in the HT29 cell extract (Figure 53.2b). 
5.3.3 C-terminal truncation of OWT 
A band of M, 24,000 was seen with the C-terminal antibody in all liver extracts but not with the N- 
terminal antibody as the maximum amount of enzyme present was below the level of detection with 
this antibody. The finding of a single M, 24,000 band on immunoblots contrasted with the multiple 
bands of VYI-Mel enzyme detected by fluorography (see above). The inability of the C-terminal 
antibody to detect bands smaller than 24,000 suggests that the lower molecular weight bands 
represent C-terminal truncated enzyme (Figure 53.3-a). The possibility that these lower molecular 
weight bands were not detected by the C-terminal antibody because the enzyme was present at levels 
below the sensitivity of the antibody was ruled out by the findings of a band of Mr 24M, but not a 
smaller and more abundant Mr 22,5W band of M-Mel enzyme, seen on, the corresponding fluorogram of 
this extract, being detected by the C terminal antibody (lane 7, Figure 5.3.3b). This figure also 
indicates the value of fluorography in confirming the bands visualised on immunoblots as &-MT. The 
M, 29PM band seen on immunoblots of all lymphocyte extracts did not correspond to M-Mej &-Nff 
(by fluorography) indicating that this represented a non-specific cross reaction(Figure 533b). 
5.3.4 Conformational change In 04LMT 
As previously observed with HT29 cell extract (see Chapter 4) the N-and C-terminal directed 
antibodies detected 06-MT on electroblots of SDS-PACels run with liver extracts at M, 24= (Figure 
53.2a). Anti-N-terminal antibody seemed unable to detect native enzyme, detecting only the 
methylated enzyme on electroblots. This suggests that a conformational change may occur in 06W 
on methylation revealing the N-terminal epitope (Figure 5.3A). The anti-C-terminal antibody 
reacted with both forms of the enzyme ( native and methylated) in immunoblots. No bands were 
detected when liver extracts were probed with pre-immune sera, confirming antibody specificity 
(Figure53A). 
5.3.5 Levels of active and inactive OOLMT In vivo 
An attempt was made to establish the immunoblotting procedure as a quantitative and reproducible 
method for detecting total &-Nff (native and methylated, normally present in vivo). However inter. 
blot variability in band density when quantitated by densitometry was in the order of 40% probably 
as a result of variable background staining on the electroblot strips. Nevertheless, while inter-blot 
variability was excessive, intra-blot reproducibility was ± 2-5 %. 
5.4 Discussion 
This study using SDS-PAGE/fluorography/densitometry of liver extracts confirmed the previous 
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direct enzyme assay findings of low levels of native O'ýMT In cirrhosis. Analysis of extracts 
containing ftWel &-Mr by SDS-PAGE/fluorography also allowed physicochernical analysis of the 
enzyme in cirrhotic liver tissue in an attempt to explain the low enzyme levels. 
In Ecoli, two distinct molecular weight forms of Oý-MT exist which have different functional 
characteristics, and are encoded by two different genes. The ada gene product has a Mr of 39MO and 
levels increase following exposure to methylating agents whereas the ogt gene product has a M, 
19,000 and levels are not inducible. In this study, no similar higher molecular weight forms of 06Mr, 
larger than M, 24ý=, were observed in human liver which might have explained the differences in 
enzyme levels between cirrhotic and non-<irrhotic tissue. However, molecular weight forms smaller 
than M, 24,000 were consistently seen in liver extracts exan-dned by SIDS-PAGE/fluorography which 
were not recognised by the C-terminally directed antibody, suggesting that they represent C- 
terminally truncated forms of the methylated enzyme. 
The presence of these smaller enzyme forms can be explained in two ways. Firstly, they could 
represent distinct enzyme forms encodedby differentgenes or arising from alternate splicing of 06Nff 
mRNA. Interestingly, a truncated Oý-MT RNA has been Identified in the HeT., aMR human cell line 
(Fritz and Kaina, 1992). Secondly, and probably more likely, they could be products of protease 
digestion either arising from endogenous protease processing of the normal M, 24= enzyme in vivo, 
or as a result of freeze/thawing enzyme extraction into a hypotonic buffer, procedures that are known 
to cause release of lysosomal proteases and consequent degradation of otherwise intact proteins, in 
vitro. The observed loss of up to 40% of OkMT activity in liver extracts upon storage (Chapter 3) 
supports a process of endogenous proteolytic degradation occurring over this time as it is expected 
that cleavage of an enzyme would affect activity. The enzyme in lymphocytes, however, appears 
more stable as shown by the maintenance of activity during prolonged storage. This contrasts with 
the more extensive enzyme cleavage that was seen when the lymphocyte extracts were examined by 
SDS-PAGE/fluorography, compared to liver extracts. These conflicting findings could be explained if 
C-terminal degradation was not associated with loss of enzyme activity. Indeed, recombinant protein 
which has been C-terminally truncated by 22 amino acids resulting in a protein of A19,700, similar 
to the smallest molecular weight form seen in liver in this study, retains functional activity (Elder et 
al, 1992). Interestingly, it seems that even N-terminal truncated OkMT, which has been reported for 
the yeast enzyme, also retains enzyme activity Xiao and Samson, 1992). The existence of both N and 
C-terminally truncated &-MT taken together with the genetic diversity seen In the N and C- 
tern-dnal across species (Potter et al, 1991) suggests that these regions are not essential for functional 
enzyme activity. 
The C-terminally truncated enzyme forms seen in this study were detected as [lWe]06-MT in liver 
extracts by SDS-PAGE/fluorography. They may, therefore, represent native OkMT which had been 
degraded in vivo, prior to in vitro methylation. Alternatively, in vitro methylation may have 
triggered C-terminal truncation (Figure 5.4). The trigger for protease degradation may be a 
conformational change in the enzyme on methylation. A conformational change in &-MT has been 
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suggested to occur in the E coli protein on alkylation (Lindahl et al, 1988) and in this study the 
inability of the N-terminal directed antibody to recognise both native and methylated enzyme 
suggests that a conformational change n-dght also occurs upon methylation of 01-Nff in human liver. 
It is unknown how the inactive methylated protein is degraded in vivo, although several studies 
have tried to answer this question. Pegg et al (1991b) has suggested that in HT29 cells 06Nff 
methylation is followed by rapid total enzyme degradation as Opposed to progressive C-terminal 
truncation. Rapid enzyme degradation does not appear to occur in all cell types as Zhukovskaya et 
al, (1992) have detected endogenously methylated enzyme in cell extracts. They also showed 
differences in the ratio of native to methylated enzyme between different cell lines suggesting that 
the rate of enzyme degradation varies between cells. The findings of different C-tern-drially truncated 
enzyme forms in liver and lymphocytes in this study suggests that the pattern of degradation is also 
tissue-specific but not disease-specific as similar C-terminal truncated forms were seen in cirrhotic 
and non-cirThotic liver. An attempt to discover whether the rate of enzyme degradation differed 
between cirrhotic and non-cirrhotic liver by measuring the ratio of native to endogenously 
methylated Oý-MT was unsuccessful because of the difficulty in quantitating the enzyme in 
immunoblots. 
This study has confirmed the finding by direct enzyme assay (Chapter 3) of low levels of Oklvff in 
association with cirrhosis. Furthermore, it has demonstrated that these low levels are not a 
reflection of either the differential expression of multiple molecular weight forms or the presence of 
smaller C-terminal truncated enzyme forms which have lost activity. Understanding the mechanisms 
underlying the low expression of 06-MT in cirrhosis will depend on further characterisation of factors 
controlling enzyme synthesis and degradation in vivo. 
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5.5 Summary 
DNA Repair By 06. MT in Cirrhotic Liver 
o 06-W levels (mean±S2vl) as detemiined by SDS-PAGE/fluorography/ 
densitometxy 
Normal liver (n=4) 853±121 IOD/mg protein 
Non-cirrhotic diseased liver (n=1 7) 781±71 IOD/mg protein 
Cirrhotic liver (n--15) 393±54 IOD/mg protein 
* 06-W levels were significantly lower in cirrhotic liver than non-cirrhotic 
diseased liver (p--0.0002) or normal liver (p---0.0015) 
Physicochemical analysis of 06. MT 
* Conformational change in Ok-MT appears to occur in liver tissue 
following methylation 
Multiple molecular weight forms of Ok-MT 
- No molecular weight forms of 06-MT higher than M,, 
24,000 were identified in liver extracts. 
- Several lower molecular weight forms at A 23200, 
21,800 and 20,900, representing C-terminally truncated 
enzyme, were present in normal, non-cirrhotic and 
cirrhotic liver 
* More extensive C-terminal enzyme degradation was 
present in lymphocyte extracts compared to liver tissue. 
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Chapter 6 
Expression Of Mutant p53 In Hepatocellular Carcinoma 
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6.1 Introduction 
Persisterice of the promutagenic DNA base lesion 06-methylguanine, due to low levels of the repair 
enzyme 06-Nff, is known to lead to G to A transition mutations. Such mutations are commonly found 
within the p53 tumour suppressor gone in a wide range of human turnours. Thus, the process whereby 
HCC develops in a cirrhotic liver may involve the occurrence of mutations within the p53 gene 
because of failure to repair Ok-methylguanine. 
The p53 turnour suppressor gene is located on the short arm of chromosome 17 (reviewed by Levine et 
al, 1991). It encodes a 53kd nuclear phosphoprotein which is expressed at low levels in normal cells 
which has the ability to complex with viral and cellular antigens (Lane and Crawford, 1979; Kern et 
al, 1991). Its precise function remains to be fully elucidated but It is likely to be Involved in 
controlling cell proliferation as levels of the protein are Influenced by the cell cycle and 
microinjection of antibodies to p53 prevent cells entering S phase (Reich and Levine, 1984; Mercer ct 
a], 1982). Initial reports suggested that p53 levels were elevated in many human tumour derived cell 
lines in contrast to normal cells and that co-transfection of p53 with the ras oncogene resulted in 
cellular transformation (Lane and Crawford, 1979; Jenkins et al, 1988). This led to p53 being initially 
considered as an oncogene product. However, subsequent reports showed that the p53 clone used in 
these initial studies was mutant (Hinds et al, 1989). Moreover, wild type p53 was shown to be 
capable of suppressing cell proliferation and transformation (Finlay et al. 1989). Thus, p53 is now 
considered to act as a tumour suppressor gene with its involvement in cellular transformation being 
mediated either by loss of wild- type suppressor activity or by gaining dominant transforming 
activity through a mutation (Lane and Benchimol, 1990). Mutant p53 can transform cells in culture in 
the presence of low levels of wild type p53 (Hinds et al, 1989). This appears to be through its 
ability to bind to and inhibit the native protein as well as stimulating cell growth in the absence of 
wild type p53- 
The genetic basis for mutant protein has been widely investigated and as a result, mutations of the 
p53 gene have been found to be a Common alteration in human Cancers (reviewed by HoUstein et al, 
1991). Mutations are usually accompanied by chromosome 17 losses involving the p53 locus on the 
other allele which reinforces the turnour suppressor function of wild type p53 (Nigro et at, 1989). p53 
mutations occur in both familial Cancer syndromes W-Fraumeni) and sporadic cancer (Srivastava et 
al, 1990; Malkin et al, 1990). Mutations are usually found within four highly conserved regions of 
the gene, namely exons 5 to 8. The exact position and nature of the p53 base changes are 
characteristic of turnour type. In human lung and liver G: C to T-A transversions predominate 
whereas G: C to A: T transitions are commoner in colon, oesophageal and brain turnours. Mutations 
are spread across exons 5 to 8 in oesophageal and lung turnours but tend to occur in CpG dinucloodde 
"hotspots" in colorectal and brain turnours. These differences are likely to reflect exposure to 
different carcinogens. 
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Abnormalities of the p53 gone in HCC were first observed in cell lines. In one study, five out of seven 
lines had abnormalities of protein expression (Bressac et al, 1990). Subsequent sequencing of the p53 
gene in HCC revealed specific mutations at codon 249 in 50% of HCC from China and south Africa, 
both areas of high aflatoxin exposure (Bressac et al, 1991; Hsu et al, 1991). These mutations were all 
G to T transversions, known to be a possible consequence of aflatoxin exposure Nuench et al, 1983). In 
support of a role for aflatoxin in causing this mutation was the demonstration, in a global study of 
p53 mutations in HCC, of a correlation between aflatoxin exposure and G to T mutations specifically 
at codon 249 (Ozturk et al, 1992). Larger studies analysing p53 mutations from different geographical 
areas have now been completed (Table 6.1). These studies have shown that in an area such as 
Britain, with low exposure to aflatoxin and Hepatitis B infection, p53 mutations are less common, 
when they do occur they are neither exclusively confined to codon 249 nor G to T transversions. 
Although the frequency of p53 mutations is high in areas where HCC is prevalent not all the 
mutations are specific codon 249 transversions suggesting that other carcinogens may be important In 
the aetiology of HCC in these areas. A significant number of p53 mutations are G to A, the type of 
DNA base damage expected from &-methy1guanine- 
Chromosome 17 allele loss occurs frequently in HCC (Nishidia, et al 1992) and often accompanies p53 
mutations Nishida et al, 1993). Point mutations do occur without allele loss and allele loss has also 
been demonstrated in the absence of p53 mutations raising the possibility of other yet unrecognised 
tumour suppressor genes on the short arm of chromosome 17 that may also be important in the 
pathogenesis of HCC (Scorsone et al, 1992). 
The biological significance of these various point mutations however is far from clear. Not all point 
mutations have the same functional effect on p53 and this includes the inability of some mutations 
to stabilise the protein (Malkin et al, 1990). As it is the mutant protein that ultimately effects cell 
regulation and thus the malignant phenotype it is important that the presence of mutant protein is 
assessed together with genetic alterations in the p53 gene. 
Although a study, from the North East Of England, has shown that only 10% of HCC had p53 gone 
mutations this was only a small study involving 19 patients (Challen et al, 1992b). The aim of this 
study was to use imrnunohistocýemistry to exan-dne a much larger series of hepatocellular carcinoma 
for the presence of mutant p53 protein. 
6.2 Patients and methods 
6.2.1 Clinical material 
Formalin-fixed paraffin-embedded archival material was available for study from 55 cases of 
hepatocellular carcinoma seen at the Freeman Hospital. These patients formed part of the 
retrospective clinical study of HCC reported in Chapter 2. The mean age of the patients was 70 
(range 43-84) with a male: female ratio of 2: 1.77% of patients had biopsy proven cirrhosis and 
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serological markers of Hepatitis B infection were present in 15 (27%) cases, 4 patients had HBsAg 
and in 11 cases HBcAb alone was present. 
6.2.2 Immunostaining 
3pm sections were cut from paraffin blocks and immunostained as described in Chapter 4 with the 
following modifications. Endogenous, peroxidase was blocked by incubation in 05% hydrogen peroxide 
in methanol for 10 minutes and the tissue was then equilibrated in TBS. Non-specific antibody 
binding was blocked by pre-incubation of the sections with either 3% normal swine serum (NSS) or 
3% normal rabbit serum (NRS), depending on whether the primary antibody was polyclonal or 
monoclonal respectively, for 10 minutes. p 53 was identified using two primary antibodies raised 
against recombinant p53 protein, CM-1 and DO-7. CM-1 is a rabbit polyclonal antibody, raised 
against human wild type p53 produced in a bacterial expression system using a full length p53 cDNA, 
and used at a dilution of 1 /1000 (Bartek et al, 1991). The monoclonal antibody DO-7, used at a 
dilution of 1 /100, is also raised against recombinant human wild type p53 and has shown to be 
specific for the denaturation-resistant epitope at the N-terminus of the protein (Vojtcsek etal, 1992). 
Incubation with 100pl per section of primary antibody was performed overnight at 41' C in a moist 
incubation tray. The sections were then washed in two 5 minute exchanges of TBS. Immunostaining 
was detected using an avidin-peroxidase system. The tissue was incubated with 1001il of 1 /1000 
biotinylated swine anti-rabbit immunoglobulin (Dako) diluted in NSS or 1001 tl of 1 /500 biotinylated 
rabbit anti-mouse immunoglobulin (Dako) in NRS for 30 minutes ' at room 
temperature, for sections 
stained with CM-1 or DO-7 respectively. Following two further 5 minute washes in TBS 100111 of 
Strep ABC complex (1pl streptavidin, 11d biotinylated peroxidase, 100pl TBS)(Dako) was placed on 
each section for a further 30 minutes. Immunoreactivity was then detected, after washes in TBS, using 
3'3 diaminobenzidine as described in chapter 4. Sections were counterstained with Mayers 
haematoxylin and mounted in DPX 
A malignant fibrohistiosarcoma. of the liver, shown to have aG to A mutation at codon 248 of the 
p53 gene, was used as a positive control. Negative controls consisted of replacement of the primary 
antibody by normal swine or rabbit immunoglobulin. 
6.3 Results 
ur JgU C Using the monoclonal antibody DO-7 immunolabelling was detected in 5/55 (9%) tumO S(F T 
6.3a). The staining was focal, involving less than 10% of the malignant cells, but of uniform intensity 
and was confined to the nucleus except in those cells undergoing mitosis. Immunostaining with the 
polyclonal antibody CM-1 was also only seen in the 4 DO-7 positive tumours with a similar focal 
nuclear distribution. However background staining was higher using CM-1 compared to DO-7 (Figure 
63a). In the 5 positive HCC cases surrounding cirrhotic tissue was present in only one and was 
negative for p53 (Figure 6.3b). In 10 p53-negative turnours, surrounding cirrhotic tissue was also 
negative. 
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Figure 6.3a: Expression of mutant p53 in hepatocellular carcinoma. (A) Intense staining 
with monoclonal antibody DO-7 within nuclei of a well differentiated hepatocellular 
carcinoma. Cytoplasmic staining is seen in those hepatocytes undergoing mitosis (arrowed). 
(B) Positive nuclear staining (arrowed) with anti-p53 polyclonal antibody CM-1 in 
malignant cells. There is greater background cytoplasmic immunoreactivity with this 
antibody compared to DO-7. 
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Figure 6.3b: Expression of mutant p53 in malignant hepatocytes as demonstrated by nuclear 
immunoreactivity with monoclonal antibody DO-7 but not in hepatocytes of adjacent 
cirrhotic tissue (arrowed). 
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The clinical features of the 4 cases expressing mutant p53 is shown in Table 6.3a. The median 
survival of these cases was 6 weeks (range 1-60) which compares to a median survival of 10 weeks 
(range 1-96) for those patients whose turnours did not express mutant p53. 
6.4 Discussion 
Although the frequency of p53 gene mutations in hepatocellular carcinoma varies geographically, 
from 10% in low incidence areas to 50% in high incidence areas (reviewed in Figure 6.1a), it is still 
unknown whether this variation is also reflected in differences in expression of mutant protein and 
cell growth. Native (wild type) p53 protein can not normally be detected immunohistochernically 
because of its short half life (Gannon et al, 1990; Oren et al, 1981). Many p53 gene mutations result in 
expression of protein with a prolonged half life and resulting cellular accumulation (Finlay et al, 
1988). The ability to detect p53 expression immunohistochemically thus usually occurs when the 
protein is mutant, but also has been shown to sometimes reflect stabilization of native protein by 
interaction with cellular and viral (eg SV40) proteins (Lane, 1979; Werness et al, 1990; Lehman et al, 
1991). More recently abnormal expression of wildtype p53 protein has been found in normal cells of a 
cancer family patient, implying impaired degradation (Barnes et al, 1992). 
In this study expression of p53 was demonstrated in 9% of British turnours. Other studies have shown 
there is overall a good correlation between p53 gene mutations and detectable protein 
immunohistochemically (Bartek et al, 1990; Davidoff et al, 1991; Rodrigues et al, 1990; Iggo et al, 
1990). In a previous British study in our laboratory of 19 HCC, two (16%) had p53 gene mutations, 
one of which was detected immunohistochemically using the polyclonal antibody CM-1 (Challen et 
al, 1992b). Combining these two studies (10 patients were induded in both studies) 5 out of 64 (8%) of 
British HCC express mutant p53 protein. 
Not only was expression of mutant protein uncommon in this series but in those cases where it did 
occur the distribution was focal. Levels of native p53 protein are known to vary throughout the cell 
cycle, accumulating during G1 and falling following cell division (Bischoff et al, 1990). Mutant p53 
protein may also be regulated by the cell cycle and the focal distribution may reflect this. A 
heterogeneous pattern of p53 gene mutations has also been demonstrated in nodules from multiple 
HCC in Japanese patients, suggesting a multifocal rather than donal origin for the tumour in the 
majority of patients (Oda et al, 1992b). The absence of staining in cirrhotic tissue adjacent to tumour 
expressing mutant p53 is consistent with a role for the protein in the late events of 
hepauxarcinogenesis. 
It is of interest that in gastric cancer expression of p53 mutant protein has been considered to be a 
poor prognostic indicator (Martin et al, 1992). In this retrospective study it was not possible to 
evaluate the prognostic significance of p53 expression in hepatocellular carcinoma but preliminary 
evidence suggests that it may contribute to an aggressive turnour phenotype (Laurent-Puig et al, 1992). 
A prospective study is now necessary to investigate the value of p53 expression as a prognostic 
indicator. 
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Table 63a: Clinical features of patients with HCC expressing mutant p53. 
Age 60 76 77 44 
Sex m m m F 
Aetiology Cryptogenic 
cirrhosis 
No cirrhosis Cryptogenic 
cirrhosis 
HBV-related 
cirrhosis 
HBs Ag Negative Negative Negative Positive 
aFP UU/1) <10 670 90000 92000 
Survival (weeks) 
160 
- .1. 
6 unknown' 
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This study has demonstrated the feasibility of detecting mutant p53 in paraffin-embedded material. 
Immunoreactivity with the novel reagent DO-7 was comparable to that seen with CM-1 but with the 
advantage of significantly less background staining. A large prospective analysis of p53 expression 
with DO-7 is therefore possible using routinely processed paraffin-embedded biopsy material rather 
than frozen tissue (Laurent-Puig et al, 1992). 
The low frequency of p53 gene mutations seen in British HCC is reflected in a similar frequency of 
mutant protein expression. These findings when taken with p53 data from other areas of the world 
indicates that there are marked geographical difference in aberrant p53 expression in HCC. This 
suggests differences in the molecular mechanisms of hepatocarcinogenesis with p53 being less 
important in low incidence areas such as Britain. 
The results of this study also indicate that p53 is unlikely to be involved in the process of 
hepatocarcinogenesis through the mechanism of DNA damage occuring in cirrhotic tissue because of 
failure to repair 0ý-rnethylguanine. The possibility that G to A mutations occuring in other oncogenes 
and tilmour suppressor genes play a Tole in the development of hepatocellular carcinoma in cirrhosis 
requires further evaluation. 
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6.5 Summary 
Expression Of Mutant p53 
*Detected immunohistodiemically using two antibodies raised against 
recombinant P53 (Polyclonal CM-1 and monoclonal DO-7) with comparable 
focal, nuclear staining. 
9 HCC (n = 55) * 5/55 (9%) positive 
*Cirrhotic tissue surrounding HCC (n--l 1) * 0/11 (0%) positive 
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Chapter 7 
Expression Of C-erb B-2 Oncoprotein in 
Hepatocellular Carcinoma 
109 
7.1 Introduction 
C-erb B-2 is a proto-oncogene located on chromosome 17 (Fukushige et al, 1986) which encodes a 
transmembrane phosphoglycoprotein of M, - 190M (Yamamoto et al, 1986). The protein consists of an 
external domain linked to an internal domain by a transmembrane region, and has a 50% homology 
with the epidermal growth factor receptor (EGFR). Its homology with EGFR has led it to be 
considered as a growth factor receptor although its ligand is still unknown. 
Overexpression of the c-erb B-2 protein has been reported in many malignant cell lines (Gullick et al, 
1987) and human turnours, such as breast (Slamon et al, 1987), bladder (Wright et al, 1991) and lung 
(Roncalli et al, 1991). Protein overexpression correlates with gene amplification (Venter et al, 1987) 
which appears to be one mechanism whereby the c-erb B-2 proto-oncogene is activated. Neu, the rat 
equivalent of c-erb B-2, by contrast is activated by point mutations (Bargmann et al, 1986). A direct 
role for C-erb B-2 in turnorigenesis is suggested by the finding that expression of activated c-neu in 
transgenic mice induces malignant transformation of mammary epithelium (Muller et al, 1988). 
Moreover, exposure of neu transformed cell lines to monoclonal antibodies, raised to the external 
domain of the protein, results in loss of the transformed phenotype suggesting an additional role for 
the protein in maintaining the transformed phenotype (Drebin et al, 1986). Gerb B-2 overexpression 
has been associated with a poor prognosis in breast carcinoma (DyIdns et al, 1991). The observation 
that turnour growth in rats can be inhibited in vivo by the use of monoclonal antibodies directed 
against the external domain of neu has raised the possibility of using immunotherapy targetted to 
the c-erb B-2 protein in human turnours, (Drebin et al, 1988). 
A preliminary study recently suggested that 80% of HCC overexpress c-erb B-2 oncoprotein as 
demonstrated immunohistochemically using a polyclonal. antibody (Voravud et al, 1989). This is 
much higher than that reported in other turnours, such as breast cancer where the incidence is 20-,. Wo 
(Corbett et al, 1990) and suggests a role for this protein in human hepatocarcinogenesis. It also raises 
the possibility of using immunotherapy against the c-'erb B-2 oncoprotein in the treatment of HCC 
which might improve the prognosis of what is presently a relatively chemotherapeutic resistant 
bznuLr. ' 
The aim of this study was therefore to analyse the expression of c-erb B-2 hepatocellular carcinoma 
patients in the North East of England using a highly specific monoclonal antibody to detect the 
protein immundhistochen-dcally. 
7.2 Patients and methods 
Archival formalin-fixed paraffin-embedded liver biopsy material from 26 cases of HCC was 
available for study, sufficient material only remaining in 26 of the 55 cases examined for mutant p53 
in Chapter 6. Clinical information was obtained on all patients from medical records. All 26 patients 
were European Caucasian with the exception of 1 patient with HCC who was Japanese. The age 
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range of the patients was 54-73 with a male to female ratio of 19 to 7. Four patients had serological 
markers of hepatitis B infection WsAg) and 23 patients has serum c(- fetoprotein levels greater 
than 5001U/I (normal <10). 
Immun6histochernistry was performed as described in Chapter 4. Briefly 3prn sections were cut from 
tissue blocks. Endogenous peroxidase activity was blocked with 05% hydrogen peroxide in methanol 
for 10 minutes. The primary monoclonal antibody NCL-CBl 1 was raised against a synthetic peptide 
corresponding to the C-terminus, of the internal domain of the c-erb B-2 protein (Corbett et al, 1990). 
Sections were incubated overnight at VC with a1 in 40 dilution of NCL-CB11. Immunostaining was 
then performed using an indirect immunoperoxidase method. The secondary antibody was a 
peroxidase-conjugated mouse ant-rabbit antibody (Dako) used at a dilution of 1 in 20. A positive 
control (a case of breast carcinoma known to over express c-erb B-2) was induded in all experiments. 
7.3 Results 
The presence of cell membrane labelling was considered an essential criterion for identification of c- 
erb B-2 overexpression; this pattern is demonstrated by the positive breast control in Figure 73a. 
Only 2 out of 26 HCCs, had membrane staining and in both cases the immunoreactivity was focal. One 
of these was a clear cell variant of HCC; the intensity of the membrane staining was much weaker 
than in the breast control (Figure 73a). The trabecular tumour which over expressed c-erb B-2 had 
also stained for mutant p53 in Chapter 6. Weak cytoplasmic staining was also seen in 5 out of 26 
HCCs (Figure 7.3b). 
7.4 Discussion 
The c-erb B-2 oncoprotein is a bmismembrane receptor and positive immunohistochemical staining in 
the form of membrane immunoreactivity has been shown to correlate with overexpression of the 
protein and gene amplification in breast cancer. In this study, only 2 out of 26 hePatocellular 
carcinoma showed such positive membrane staining using a recently developed monoclonal antibody 
to the c-erb B-2 protein NCIPCB11. These results contrast markedly with those reported by Voravud 
et al (1989) who found that 12/14 (86%) of hepatocellular carcinoma stained positively with the 
polyclonal antibody, 21N to the c-erb B-2 oncoprotein. However, they did not distinguish between 
cytoplasmic and membrane staining when reporting their findings. This is important as the 
significance of cytoplasmic staining remains one of conjecture; cytoplasmic staining in the absence of 
membrane staining does not correlate with overexpression of c-erb B-2. 
Cytoplasn-dc staining has been reported with both the polyclonal antibody 21N and the monoclonal 
antibody NCL-CBl 1 (Corbett et al, 1990). In this study, cytoplasmic irnmunoreactivity was detected 
in 5/26 (19%) of tumours. Possible explanations for cytoplasmic staining include crossreactivity with 
an unknown protein, as both antibodies react with a band of M, 150,000 on Western blotting (Corbett 
et al, 1990; Gullick et al, 1987), abnormal processing of the RNA and protein, or internalisation of 
the c-erb B-2 receptor. Internalisation of the epidernal growth factor receptor, which has homology 
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with the c-erb B-2 protein, has been demonstrated in epidermoid carcinoma (A431) cells (Nfiller et al, 
1986). In that study EGFR was demonstrated on both the Cell surface and endosomal compartments in 
a transfer pathway of EGF/EGFR complex to the lysosomes. C-erb B-2 has also been demonstrated 
immunohistochemically in endoplasmic reticulum. using electron n-dcroscopy (Miller et al, 1986). In 
the 2 HCCs which showed cytoplasmic staining in this study, no c-erb B-2 RNA was detected 
confirming that overexpression of c-erb B-2 oncogene, comparable to that found in breast 
adenocarcinorna was not occuring (Collier et al, 1992). 
The results thus Indicate that overexpression of the c-erb B-2 proto-oncoprotein is uncommon in 
hepatocellular carcinoma and is therfore unlikely to be important in hepatocarcinogenesis. Moreover 
immunotherapy using the c-erb B-2 transmembrane receptor cannot be considered as potential therapy 
in these turnours. 
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7.5 Summary 
C-erb B-2 Oncoprotein Expression in HCC 
o 2/26 (8%) membrane immunoreactivity 
* 5/26 (19%) cytoplasmic immunoreactivity 
Overexpression of c-erb B-2 oncoprotein is uncommon in British HCC 
115 
Chapter 8 
Expression Of Transforming Growth Factor Alpha In 
Hepatocellular Carcinoma. 
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8.1 Introduction 
Transforming growth factor alpha (TGF-a) is a 50 amino acid mitogenic secretory polypeptide which 
has 30% homology with the 53 an-dno acid epidermal growth factor (reviewed by Derynck, 1988). It 
binds to the epidermal growth factor receptor (EGFR) (Todaro, et al, 1980; Massague, 1983) and thus 
activates receptor tyrosine kinase activity leading to autophosphorylation, a prerequisite for 
stimulating DNA synthesis (Reynolds et al, 1981). 
The TGF-a gene, located on chromosome 2, was cloned in 1984 and found to encode a 160 amino acid 
precursor polypeptide (Derynck et al, 1984). This precursor consists of a 100 amino acid extracellular 
domain that includes the N -terminal signal sequence and the 50 amino acid mature peptide, a 
hydrophobic transmembrane domain and 35 amino acid cytoplasmic domain. This transmembrane 
precursor is proteolytically cleaved at the cell surface resulting in secretion of mature TGF-a. Both 
the mature TGF-a and the transmembrane precursor are biologically active (Brachmann et al, 1989; 
Wong et al, 1989) 
TGF-a was first isolated from the culture medium of retrovirally transformed fibroblasts and 
subsequently from other transformed cells but not the parental cell lines suggesting a role in 
transformation (De Larco et al, 1978; Kaplan et al, 1980). This was supported by transfection studies 
in which rat fibroblasts transfected with human TGF-a cDNA lost anchorage-independant growth 
and formed TGF-a secreting turnours when injected into nude mice (Rosenthal et al, 1986). In man, 
TGF-a RNA has been detected in a range of malignant cell lines and turnours (Derynck et al, 1987). 
In the liver TGF-a mRNA production increases in rat hepatocytes (but not non-parenchymal cells) 
following partial hepatectomy and is temporally related to increased DNA synthesis and rising 
EGFR mRNA. This suggests that TGF-a acts as a mediator of liver regeneration through an autocrine 
loop (Mead and Fausto, 1989). Identification of immunoreactive TGF-a in proliferating hepatocytes of 
rat liver following carbon tetrachloride induced damage lends further support to this hypothesis 
(Burr et al, 1993). 
Several pieces of evidence suggest that TGF-a may be important in hepatocarcinogenesis. First, a 
number of HCC cell lines, including the human HCC cell line HepG2, synthesize and secrete TGF-a 
(Derynck et al, 1987, Liu et al, 1988; Luetteke et a], 1988). Second, in transgenic mice human TGF-a 
overexpression results in the development of multifocal hepatocellular carcinoma Ohappan et al, 
1990). Finally, high urinary levels of TGF-a have been detected in patients with hepatocellular 
carcinoma(HCC) (Chuang et al, 1991; Yeh et al, 1987). 
The aims of this study were (a) to immunolocalise TGF-a in normal human liver, (b) to identify the 
expression of TGF-a in human HCC indicated by the presence of mature peptide using 
immunohistodiemistry, (c) to compare TGF-a immunoreactivity in tumour and cirrhotic tissue from 
individual patients. 
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8.2 Materials and methods 
8.2.1 Case Material 
10% buffered formalin-fixed paraffin-embedded archival material from 28 cases of hepatocellular 
carcinoma were studied; the presence or absence of mutant p53 and c-erbB-2 mcoprotein had been 
established immunohistochen-dcafly in these cases in the previous chapters. In 20 cases, turnours, had 
developed on a background of established cirrhosis, non-tumour tissue was available for study in 13 of 
these. Four cases of normal human liver was also included for inununohistochen-dcal analysis. Full 
clinical details were obtained from medical records 27 patients were European Caucasian, the male to 
female ratio was 1.8.1.. and 19 patients had an a fetoprotein level of >500pg/l. Serological markers 
of Hepatitis B virus infection were present in 9 patients, 4 had HBsAg and 5 with HBcAb alone. 
8.2.2 Immu no histo chemistry. 
3pm sections were used for immunostaining, as described in Chapter 4 with the following 
modifications. Following hydration through graded alcohols endogenous peroxidase was blocked 
with 05% hydrogen pero)dde in methanol for 10 minutes and the sections were preincubated with 
0.1% trypsin for a further 10 minutes. The primary antibodies used were a polyclonal antibody 26T 
(gift of Dr W Gullick, ICRF, Hammersn-dth Hospital, London) used at a dilution of 1 in 20 (Barton et 
al, 1991) and a monoclonal antibody Ab-2 (Oncogene Science) diluted to 1 in 20 (Sorvillo et al, 1990). 
All incubations with primary antibody were performed at VC overnight. Immunoreactivity with the 
polyclonal antibody 26T was detected using an indirect immunoperoxidase method as described in 
Chapter 4. Staining with Ab-2 was detected using an avidin-biotin system (ABC) with biotinylated 
rabbit anti-mouse arununoglobulin antibody as the secondary antibody as described in Chapter 6.33 
Dian-dnobenzidine was used as the chromagen in all experiments. Pre-incubation of primary antibody 
with cognate peptide and omission of the primary antibody acted as negative controls. Sections of 
duodenal mucosa known to eq)ress TGF-a were used as a positive control. 
8.3 Results 
8.3.1 Normal liver 
Using the antibody Ab-2, TGF-a immunoreactivity was seen in very occasional hepatocytes with 
strong cytoplamic staining in bile duct epithelium. Labelling was absent from perisinusoidal cells 
(lipocytes), Kupffer cells and sinusoidal. endothelial cells. Intense staining was also seen in bile duct 
epithelium stained with 26r but in a membrane rather than a cytoplasn-dc distribution. 
8.3.2 Tumours 
4/28 cases of HCC showed membrane immunoreactivity with 26r (Figure 8.3.2). There was associated 
cytoplasmic staining in 3 cases but this was absent from a single case of dear cell variant of HCC. A 
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Figure 8.3-2: TGF-(x expression in hepatocellular carcinoma. (A) Membrane 
immunoreactivity (arrowed) in a clear cell variant of hepatocellular carcinoma with the 
polyclonal antibody 26T. (B) Cytoplasmic immunolabelling within the same tumour with 
the monoclonal antibody Ab-2 (arrowed). 
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further 8 tumours had cytoplasmic staining, but no membrane immunoreactivity, although this was 
weak and in 4 cases was only focal. The 12 cases which had shown positive immunoreactivity with 
26r also stained with Ab-2 but staining was confined to the cytoplasm with no apparent membrane 
accentuation(Figure 832). No Ab-2 positive 26r-negative tumours were identified. Pre-incubation 
with cognate peptide abolished TGF-a membrane and cytoplasmic immunoreactivity. 
8.3.3 Cirrhosis 
Only 1/13 cases of cirrhosis showed immunoreactivity, within hepatocytes, with anti TGF-a and this 
was cytoplasn-dc with both 26r and Ab-2 antibodies (Figure 833). In this TGF-a positive case HBsAg 
was present whereas the other 12 cases of cirrhosis exan-dned were not hepatitis B virus related The 
adjacent tumour from this case had shown similar staining limited to the cytoplasm. In 4/12 of the 
remaining cases TGF-a expression was limited to the turnour. Immunostaining was also seen in 
residual bile ducts and proliferating ductules in cirrhotic cases (Figure 833). 
8.4 Discussion 
This study has demonstrated the presence of immunoreactive TGF-a in occasional parenchymal cells 
of normal human liver and strong staining in bile duct epithelium. The possibility that bile duct 
epithelium exists as a source of TGF-a has not been previously considered but it is consistent with the 
presence of TGF-a mRNA and protein in other normal human glandular epithelial tissues such as the 
gastrointestinal tract (Malden et al, 1989). No detectable TGF-a was found in perisinusoidal cells, 
sinusoidal endothelial cells or Kupffer cells. It is of interest that fixed tissue macrophages; in other 
tissues have been shown to express the peptide (Rappolee et al, 1988). Although lack of TGF-a 
immunoreactivity in Kupffer cells may reflect functional heterogeneity of macrophages in growth 
factor production, the possibility that these findings are a reflection of rapid secretion of TGF-a 
from hepatic macrophages (Kupffer cells), resulting in undetectable cellular protein, cannot be 
excluded. In previous studies, macrophage TGF-a production was detected using sensitive RNA 
detection methods rather than analysis of immunoreactive protein. 
TGF-a expressiort, as demonstrated by membrane and cytoplasmic immunoreactivity, was seen in 8/28 
(28%) of HCCs. The pattern of staining probably reflects the synthetic pathway of TGF-a as the 
antibodies used react with both the mature protein and its precursor (Barton et al, 1991; Hazarika et 
al, 1987). The 160 amino acid precursor, containing the mature 50 amino acid TGF-a, is translated in 
the endoplasmic reticulum where it is anchored to the membrane by its C-terminus. Mature peptide is 
then cleaved during transport to the plasma membrane where it is secreted and available for 
membrane interaction (reixido et a], 1987; Bringman et al, 1987). Cytoplasmic immunoreactivity 
therefore represents either precursor or mature TGF-a whereas membrane staining suggests either 
persistent membrane bound precursor or secreted TGIF-a bound to its receptor (EGFR). 
Membrane staining was not seen with the monoclonal anti-TGF-a antibody Ab-2 and is likely that 
this reflects binding to a different region of TGF-a from 26T as Ab-2 was raised against the 50 an-dno 
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Figure 8.33: TGF-a expression in cirrhosis. (A) Cytoplasmic staining with Ab-2 within 
hepatocytes (arrowed) in a case of hepatitis B related cirrhosis. (B) Cirrhotic tissue at a 
higher magnification illustrating the associated strong immunoreactivity within residual bile 
ducts and proliferating ductules (arrowed). 
1.2.1 
acid TGF-a peptide and not the 17 amino acid C-terminus used to produce the polyclonal antibody 
26T (Barton et al, 1991; Sorvillo et al, 1990). However, synthesis of TGF-a by these malignant 
hepatocytes is supported by the detection of specific RNA from 2 turnours which exhibited TGF-a 
immunoreactivity (Collier et al, 1993). 
EGFR, required to complete an autocrine loop of TGF-a stimulation, is known to be present on 
hepatocytes (Dunn et aI, 1986). However in vitro studies to document the effect of TGF-a or EGFR 
antibodies on hepatocellular carcinoma cell growth, in order to verify this hypothesis, are still 
awaited. In addition to the postulated autocrine role of TGF-a in hepatocarcinogenesis expression of 
the peptide by malignant cells may exert paracrine effects on surrounding mesenchymal cells. The 
vascularity of HCC may be partly explained by paracrine effects of TGF-a which is known in vitro 
to cause vasodilatation by a direct action on vascular epithelium (Gan et al, 1987). Paracrine effects 
of hepatocyte and bile duct-derived TGF-a on perisinusoidal cells Gipocytes), which are important in 
hepatic fibrogenesis, is also suggested by the finding that TGF-a stimulates the proliferation of 
cultured perisinusoidal cells in vitro (Bachern et al, 1989). HCC subtypes characterised by excess 
extracellular matrix, such as sclerosing and fibrolamellar variants, may be rich in TGF-a; studies to 
investigate this are now indicated. 
The importance of studying non-tumour tissue when investigating the role of growth factors in 
carcinogenesis has been emphasized by a recent study of TGF-a in colorectal cancer as tumour 
expression mirrored that in surrounding normal tissue Malden et al, 1989). However, differences were 
noted in our study when HCC was compared with that of surrounding cirrhotic tissue. In 5 TGF-a 
positive turnours in which surrounding cirrhotic tissue was present, only one case showed 
immunoreactivity within parenchymal cells of cirrhotic nodules. These results contrast with those of 
a recent study from China where over 80% of cirrhotic tissue from patients with HCC stained with 
Ab-2 as did the equivalent number of tumours (Hsia et al, 1992). However, all these patients had 
HBV-related cirrhosis in contrast to the cirrhotic group in this study in which only one was HBsAg 
positive. It is of note, however, that this was the only case expressing TGF-a in both cirrhotic and 
tumour tissue. The presence of immunoreactive TGF-a in HBV-related cirrhosis and tumours, may 
reflect impaired peptide secretion due to coexistant viral infection, as colocalisation of HBsAg and 
TGF-a has been observed in individual cells (Hsia et al, 1992). An alternative explanation is that 
HBV upregulates TGF-a expression which is supported by the observation that TGF-a RNA levels 
increase following transfection of the hepatoblastoma cell line, Hep G2, with HBV (Tabor et al, 
1992). TGF-a upregulation may therefore be invoved in the pathogenesis of TiBV-related HCC. 
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8.5 Summary 
Expression Of Transforming Growth Factor alpha 
Normal liver * expression confined to bile duct epithelium. 
HOC * 8/28 (28%) expressed TGF-a as indicated by cytoplasmic 
immunoreactivity (Ab-2) and membrane and/or 
cytoplamic staining with 26T. 
Cirrhosis 1, cirrhotic tissue surrouding HCC positive tumours, only 
expressed TGF-a in 1/7 cases. This tumour was the only 
HBs Ag tumour examined. 
* no TGF-a expression was seen in tissue surrounding 
HCC negative cases 
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Chapter 9 
Final Discussion 
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The following discussion will focus on two issues; firstly, the significance of the finding of low levels 
of the DNA repair enzyme 06-MT in cirrhotic tissue with respect to the risk of developing HCC; 
secondly, on the role of oncogenes, turnour suppressor genes and growth factors on 
hepatocarcinognesis in Britain, and in comparison to other geographical areas. 
06-MT levels, measured using the direct enzyme assay, described in Chapter 2, were significantly 
lower in cirrhotic tissue compared to non-cirrhotic diseased liver and normal liver, the lack of 
correlation seen between diseased liver and lymphocyte levels indicated that this deficiency is tissue- 
and disease-specific. These enzyme assay findings were confirmed by SDS-PAGE of extracts 
followed by flurography and quantitiative densitometry where the native enzyme which had been 
methylated and radiolabelled was detected as an expected M,, 24,000 band. This suggests that 
cirrhosis may be a risk factor for HCC because of the persistence of the unrepaired DNA base lesion 
06-methylguanine, which in the presence of cell proliferation, a characteristic feature of cirrhosis, is 
known to produce G to A transition mutations, a known mechanism of oncogene activation. The risk 
of HCC developing in a cirrhotic liver is also dependant on advanced age, male sex and actiology of 
cirrhosis. In the context of the interindividual variation in enzyme levels in cirrhotic tissue it is 
tempting to speculate that these factors may also affect Cf-Mr levels. A larger study of cirrhotic liver 
tissue is now required to fully establish the relationship between these other risk factors and 06-Mr 
levels. The relative contribution of environmental and hereditary factors to liver enzyme levels is 
unknown. It might be possible to assess any genetic component if it could be shown that lymphocyte 
levels correlated with levels in normal liver, so allowing the latter to be used as a surrogate marker 
for normal tissue levels. This would allow 06-MT levels to be measured in a large group of cirrhotic 
and non-cirrhotic patients and their families. 
The disadvantage of assessing 0'-MT levels in cirrhotic liver extracts is that it does not take into 
account differences in enzyme levels at the cellular level; namely between parenchymal and non- 
parenchymal cells, and between individual hepatocytes. It is more likely that the number of 
hepatocytes not expressing 06-MT will be more important in determining the susceptibility of 
cirrhotic tissue to DNA base damage than the overall tissue levels. UnfortuantlY the peptide 
antibodies raised to 06-MT in this study were unable to immunolocalise the enzyme in tissue 
sections. However, 06-MT has recently been demonstrated in normal liver by another group using 
antibodies raised against recombinant enzyme (Lee et al, 1992). In that study 06-MT was localised to 
hepatocytes but the distribution was heterogenous. It is likely, but as yet unproven, that such 
heterogenous 06-MT expression also occurs in cirrhotic liver. Sufficient amounts of recombinant 
enzyme are now available to allow polyclonal antibodies to be developed in an attempt to assess the 
distribution of 06-MT in cirrhotic tissue; this work is currently in progress. 
The tissue expression of 0'-MT can also, potentially, be evaluated using in situ hybridisation for 
mRNA. A successful method has been reported using a digoxygenin labelled oligonucleotide in 
human kidney (Wani et al, 1992). In preliminary work, which I have carried out, it has not been 
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possible to reproduce these findings in human liver (unpublished observations), and the finding of 
non-specific nuclear staining, similar to that reported by Wani et al, throws doubt on the specificity 
of their findings in human kidneyý. The use of multiple oligonucleotides or riboprobes, possibly 
radiolabelled with V5S] rather than digoxygenin, may be needed to improve the sensitivity of in situ 
hybridisation for 06-MT RNA. 
The mechanism underlying the low levels of 06-MT observed in cirrhosis remain one of conjecture 
as the factors controlling enzyme synthesis and the normal rate of cell turnover are still unknown. 
The presence of C-terminal truncated enzyme has been previously reported in human liver. 
Although this was confirmed in the present study in both cirrhotic and non-cirrhotic tissue this 
enzyme form appears to retain enzymatic activity, and cannot therefore account for the low levels 
seen in cirrhosis. 
Although the finding of low levels of 06-MT in cirrhosis suggests increased susceptibility to 
alkylating agent damage, and hence mutation and carcinogenesis it must be emphasised that the 
level of 06-MT is only one factor determining a suseptibility of a tissue to environmental carcinogens. 
The other factors include the ability of the liver to metabolise alkylating agents to reactive 
metabolites, the extent to which DNA damage occurs as well as the extent of DNA proliferation at 
the time of adduct formation. Ideally all four factors need to be assessed In cirrhotic tissue 
simutaneously before an assessment of an individuals risk of developing HCC can be made. Another 
complicating factor is that carciriogenesis is a dynamic process with the sequence of events leading 
to HCC occuring over a prolonged time period. Ideally 06-MT needs to be measured on serial liver 
biopsies, from normal through cirrhosis to the time of turnour development. Levels of 06-MT have 
been measured in HCC and periturnour liver tissue in a study of 21 patients from Japan (Isowa et al, 
1991) but there was little difference in enzyme levels between tumour and surrounding liver tissue. 
As these tumours appeared to have occured on the basis of a non-cirrhotic liver it would be 
interesting to know whether the levels in the periturnour tissue differed from enzyme levels in 
cirrhotics uncomplicated by HCC and cirrhotic tissue surrounding HCC in Japanese patients. 
The contribution made by G to A mutations, produced by 06-alkylguanine, to hepatocarcinogenesis 
is dependant on these mutations occurring within the coding region of proto-oncogenes or tumour 
suppressor genes involved in cell proliferation and differentiation. The sequence of events in terms of 
oncogene activation, altered tumour suppressor gene function and the role of peptide growth factors, 
which occur during tumorigenesis are unresolved. A genetic model has been proposed for colon 
cancer where the availability of preneoplastic tissue has allowed the sequence of molecular events to 
be evaluated (Fearon and Vogelstein, 1990). The salient features of this model are: firstly, mutational 
activation of oncogenes and inactivation of tumour suppressor genes both occur; secondly, mutations 
in at least four to five genes are required for tumour production; and thirdly, the total accumulation 
rather than the order of molecular events is responsible for determining the tumour's biological 
properties. The difficulty in applying this model to HCC is the lack of a recognised early stage of 
malignant transformation. However, as in colon cancer multiple pathways appear to occur. In HCC 
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these different pathways appear to be geographically determined, probably related to different 
aetiological factors. This is demonstrated in Table 9 which shows that whilst expression of mutant 
-erb B-2 oncogene product and TGF-a are uncommon in Britain, compared to HCC from high p53, c 
incidence areas, the opposite is seen with ras mutations. The high incidence of codon specific p53 
inutations in high incidence areas has been explained by an epidemiological association with 
aflatoxin exposure. However, interestingly, site-specific p53 mutations do not occur in aflatoxin-B, 
induced rat hepatic hyperplastic nodules (Hulla et al, 1993). The presence of p53 mutations in 
turnours from areas of low aflatoxin but high hepatitis B exposure suggests the latter may prove to 
have a role in producing these mutations. Certainly TGF-a expression appears to be up regulated by 
hepatitis B infection and is probably involved in the pathogenesis of HBV- related HCC. 
We are still far from fully understanding the mechanisms involved in human hepatocarcinogenesis. 
This work has, however, suggested the existence of different pathways probably determined by the 
involvement of different aetiological agents. Thus as further oncogenes and turnour suppressor genes 
are recognised their expression must be assessed in HCC from both high and low incidence areas. 
The role of alkylating agents and other environmental carcinogens deserve further study in HCC 
from Britain in the context of the lack of an association with a recognised aetiological agent in most 
tumours. As cirrhosis is a universal risk factor worldwide the finding of deficient DNA repair by 
Nff in British cirrhotics needs to be evaluated in other geographical areas. The possibility that 01- 'Mr 
levels could be used as a marker to indicate an increased risk of a cirrhotic patient developing HCC 
and thus a need for closer screening is an interesting concept. The results of a prospective follow up 
study of the 48 patients studied to asertain if enzyme levels correlate with the development of IICC 
is now needed in an attempt to answer this question. 
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Table 9: Geographical differences in expression of oncogenes, tumour suppressor genes and 
growth factors in hepatocellular carcinoma. 
Oncogene/growth factor % Abnorma Expression 
Low incidence area High Incidence area 
(Britain) 
ras 24% * 0%* 
(Challen et al, 1992a) (Tada et al, 1991) 
p53 9% 29 -58% 
(Chapter 6) (Table 6.1 a) 
C-erb B-2 8% 73% 
(Chapter 7) (Voravud et al, 1990) 
TGF-a 28% 80% 
(Chapter 8) (Hsla et al, 1992) 
* gene mutations 
fie 
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